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ABSTRACT 
Monitoring the time course of drug in the skin is critical for determining the frequency 
and dose of drug administration from safety and efficacy perspectives. Intermittent blood 
sampling is used as a surrogate for approximating concentration of drugs in the tissues, which 
leads to blood loss and discomfort to patients. A novel noninvasive technique called 
“Electroporation and transcutaneous sampling” (ETS) was developed for estimating the drug 
concentration in the skin extracellular fluid. The application of ETS technique in studying 
dermatokinetics of cephalexin, ciprofloxacin, and 8-methoxypsoralen was investigated. The 
results demonstrated the ability of ETS technique in dermatokinetic studies of drugs with 
different physicochemical properties. ETS technique was also found to be a promising method 
for noninvasive estimation of blood glucose levels.  
Two novel techniques were developed for enhancing the transdermal delivery of drugs. 
“ChilDrive”, a technique of combining regional cutaneous hypothermia with iontophoresis was 
used for enhancing the bioavailability of transdermally administered drug in the deeper 
musculoskeletal tissue like synovial fluid. The bioavailability of drugs in the synovial fluid of 
knee joint was enhanced by ~6-12-fold and ~2-4-fold by ChilDrive when compared to passive 
and iontophoretic transdermal drug delivery. 
Magnetophoresis, a technique of enhancing transdermal drug delivery by application of 
magnetic field was developed. The mechanistic studies demonstrated that transdermal 
magnetophoresis of drugs was due to contribution of multiple factors such as magnetorepulsion, 
magnetohydrokinesis and magnetically enhanced partition coefficient. Magnetophoretic patch 
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system was designed and pharmacokinetic studies were performed. Magnetophoresis resulted in 
higher dermal bioavailability of drugs compared to passive transdermal drug delivery. It was also 
found from the in vitro studies that combination of chemical enhancers would further enhance 
the efficiency of magnetophoretically mediated drug delivery enhancement.  
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CHAPTER-1 
 INTRODUCTION 
 
1.1. Skin 
Skin is the outermost organ of the body which acts as a barrier protecting the body from 
physical, chemical or microbial attacks, ultraviolet radiation, acts as thermostat in maintaining 
body temperature and prevents water loss from the body. Skin comprises of two distinct regions; 
the epidermis and dermis which rests on the subcutaneous tissue (Figure 1-1) (1, 2).  
 
 
 
 
 
 
 
Figure 1-1. Structure of skin 
1.1.1. Epidermis 
 Epidermis is the outermost avascular layer with a thickness of ~0.075 to 0.15 mm. The 
epidermal layer consists of 95% keratinocytes and the remaining 5% is composed of 
melanocytes, langerhans cells and merkel cells. The epidermal region is further subdivided into 
various layers like stratum corneum, stratum granulosum, stratum 
Stratum Corneum 
Epidermis 
Dermis 
Subcutaneous tissue 
Musculoskeletal tissue 
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spinosum, and stratum basale. The outermost layer of epidermis, stratum corneum (10-20 µm) is 
the main barrier that prevents in and out entry of substances. The stratum corneum or horny layer 
represents a brick and mortar model with the dead, keratinized cells embedded in a mortar of 
lipid bilayers. It consists of 75-80% of protein which is mainly keratin and 5-15% of lipid. The 
major contents of lipid domain include ceramides, fatty acids, cholesterol, and sterol/wax esters. 
Water also plays an important role along with keratinocytes and lipid layers in maintaining the 
barrier integrity of stratum corneum. The stratum granulosum, spinosum and basale constitute 
the viable epidermis which is present below the stratum corneum. Keratinocytes, melanocytes, 
langerhans cells and merkel cells constitute the viable epidermis (3-6). 
1.1.2. Dermis 
 The layer of skin just below the viable epidermis is the dermis which constitutes the bulk 
of skin and made of fibrous and elastic tissue. The dermis has a thickness of ~2 to 4 mm and 
consists of numerous structures like blood vessels, lymphatic vessels, nerve endings, hair, 
sebaceous glands, and sweat glands. The dermal region has extensive capillary network which 
connects to systemic circulation with branching from the arterioles and venules. The lymphatic 
vessels aid in the drainage of particulate and liquid matter from the dermis. The dermis also has 
scattered fibroblasts, macrophages, leucocytes, and mast cells. One square centimeter of skin is 
associated with about three blood vessels, 360 cm of nerves, 10 hair follicles, 15 sebaceous 
glands, and sweat glands (7, 8). 
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1.2. Transcutaneous sampling of drugs 
 In general, when the infection is present in the central pharmacokinetic compartment, the 
activity of the drug is determined by the unbound drug concentration in the plasma. But, if the 
infection is in the peripheral tissue like skin, it is the time course of unbound drug concentration 
in the skin extracellular fluid (ECF) that is critical for successful drug therapy. ECF can be 
considered as a liquid compartment in the close vicinity of cells in which drugs enter. In such 
cases, monitoring drug levels in the plasma may not represent the actual levels in the affected 
peripheral tissue. Moreover, the phlebotomical procedures are associated with blood loss and 
discomfort in patients. Therefore, the time course of drugs in the affected tissue should be 
monitored for determining the frequency and dose of drug administration from the safety and 
efficacy perspectives (9-11). 
1.2.1. Different techniques of sampling drugs from the dermal ECF 
 Conventional techniques of drug sampling from the dermal ECF include skin blister fluid 
sampling and skin biopsy sampling. However, these techniques are invasive in nature and also 
have a limitation with the number of samples that can be collected (12-16). 
Microdialysis is a minimally invasive technique which is widely used for sampling of unbound 
drug from the tissue extracellular fluid. To carryout cutaneous microdialysis a small probe 
constructed with semipermeable membrane is inserted in the dermis and the principle involved is 
that the physiological solution pumped through the probe is in equilibrium with the molecules 
diffusing in the immediate surroundings (17). Microdialysis has been successfully employed for 
the estimation of drugs like diclofenac, 5-fluorouracil, ibuprofen, propranolol, and nicotine in the 
skin extracellular fluid (18-22). Microdialysis technique has certain limitations with 
implementation in therapeutic drug monitoring. The drug recovery by microdialysis is affected 
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by various physicochemical and physiological factors and the major concern is the possibility of 
damage to the skin microvasculature due to probe insertion leading to local ischemia and 
effecting tissue metabolism (17, 23). 
Reverse iontophoresis had been studied for transcutaneous sampling of caffeine, theophylline, 
valproate, and lithium levels for therapeutic drug monitoring. It is an active technique where-in 
the subdermal drug is driven to the surface of the skin by application of low intensity electric 
current through skin (10, 24-26). 
Ultrasound technique has also been used to sample interstitial fluid. This technique involves 
permeabilization of skin by ultrasound followed by collection of interstitial fluid by application 
of vacuum (10, 27, 28). 
1.2.2. Electroporation and transcutaneous sampling (ETS) 
 Electroporation is considered to be one of the promising electrically mediated techniques 
to enhance drug delivery across the skin involving reversible permeabilization of skin brought 
about by application of short electrical pulses. Transient aqueous pathways are created in the 
stratum corneum due to the application of high voltage short electrical pulses, which reseal to 
regain the barrier property. The recovery of stratum corneum barrier property depends on the 
nature, number and pulse voltage applied (29-32).  
Electroporation and transcutaneous sampling (ETS) is a noninvasive technique for estimating the 
time course of drugs in the dermal extracellular fluid. ETS is a technique of reversible 
permeabilization of stratum corneum and sampling of drugs and analytes from the dermal 
extracellular fluid by facilitating reverse diffusion of drug in the direction of dermis to stratum 
corneum. The principle of ETS is similar to that of microdialysis; in case of microdialysis, the 
recovery of the unbound drug from the dermal ECF is determined by the permeability of 
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microdialysis probe membrane whereas in case of ETS, the recovery of unbound drug is 
determined by the skin permeability. In ETS, the diffusion of free drug across stratum corneum 
is affected only by the free drug concentration in dermal extracellular fluid as the drug bound to 
plasma proteins does not diffuse across stratum corneum following electroporation. Previous 
studies have reported that electroporation is efficient in transporting molecules up to 10 kDa. 
Hence, the transcutaneous flux of the drugs is proportional to the unbound drug concentration in 
the dermal extracellular fluid (33-35). 
The main objectives of ETS project are: 
I. To develop a simple, noninvasive technique of sampling drugs and analytes from the 
dermal extracellular fluid. 
II. To study the time course of drug in the skin following drug administration by different 
routes of drug delivery. 
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1.3. Transdermal drug delivery 
Transdermal drug delivery involves the transport of drugs due to concentration gradient 
from the skin surface into the systemic circulation. Delivery of drugs across the skin provides an 
alternative to the conventional oral drug delivery and intravenous administration. The major 
advantages of transdermal drug delivery are (36, 37): 
a) Readily accessible and large surface area of skin for absorption. 
b) Avoidance of hepatic first pass effect and gastrointestinal incompatibility. 
c) Minimized side effects due to optimized blood concentration-time profile. 
d) Self administration is feasible and patient compliant. 
e) Predictable and extended duration of therapeutic activity. 
f) Reduced frequency of drug administration. 
g) Ease of termination of therapy by simple removal of drug source. 
However, transdermal drug delivery has certain limitations like: 
a) Stratum corneum layer of skin is the major barrier for delivery of drugs. 
b) Suitable for low molecular weight and slightly lipophilic drugs only. 
1.3.1. Different approaches to enhance transdermal drug delivery  
 Passive transdermal drug delivery is limited due to the barrier property of stratum 
corneum. The different approaches used to enhance transdermal drug delivery include: 
I. Chemical enhancers/penetration enhancers 
II. Iontophoresis 
III. Electroporation 
IV. Ultrasound/ Sonophoresis 
V. Microneedles 
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Chemical enhancers are widely used for enhancing the permeation of poorly penetrating drug 
molecules through the skin. Numerous compounds like sulphoxides, azones, pyrrolidones, 
alcohols, glycols, surfactants, and terpenes have been found to be efficient in enhancing the 
transdermal drug delivery. The main mechanisms for enhanced transdermal drug delivery by 
chemical enhancers or penetration enhancers include increased solubility of drug in the donor 
formulation, increased partitioning into the stratum corneum, fluidization of lipid bilayers, and 
disruption of intracellular proteins (38, 39). 
Iontophoresis is a physical technique used for enhancing the transdermal drug delivery. It 
involves the application of mild electric current, which aids in the movement of charged drug 
molecules across the skin. The amount of drug delivered depends on the electric current applied, 
duration of application and the area of skin surface to which current is applied. The main 
mechanisms contributing to iontophoresis are electrophoresis and electroosmosis. Iontophoresis 
approach had been used for enhancing transdermal delivery of drugs like 5-fluorouracil, sodium 
nonivamide, lidocaine hydrochloride, dexamethasone sodium phosphate, fentanyl, timolol, and 
acyclovir. The maximum current density that can be applied clinically is limited to 0.5 mA/cm2 
(40-46). 
Electroporation is a technique that involves transient structural perturbation of lipid bilayer 
membranes due to the application of high voltage (60-120 V) electrical pulses. Electroporation 
leads to the formation of transient aqueous pathways within the stratum corneum and the main 
mechanisms for enhanced transdermal drug delivery are electrophoresis and enhanced diffusion. 
The factors affecting transdermal drug delivery by electroporation include the pulse voltage, 
number of pulses, pulse length, physicochemical properties of drug and formulation of drug 
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reservoir. Electroporation was shown to enhance transport of drugs like timolol, metoprolol, 
fentanyl, calcein, calcitonin, and heparin (29, 31, 34, 47-51). 
Sonophoresis is a technique of enhancing transdermal drug delivery by application of low 
frequency ultrasound (20-100 kHz) on the skin. The mechanisms leading to enhanced drug 
transport by sonophoresis include cavitation, thermal effects, induction of convective transport, 
and mechanical effects. Sonophoresis was shown to increase the transdermal delivery of drugs 
like lidocaine, corticosterone, estradiol, cyclosporine, and insulin (52-58). 
Microneedle system consists of an array of micron sized needles which will penetrate the 
epidermal region of the skin to create microchannels Based on application, microneedles used 
can be solid microneedles or hollow microneedles. The effect of microneedles depends on the 
type of needles used, fabrication, needle length, width, shape, and force of insertion. 
Microneedles have been used to enhance the transdermal transport of compounds like 
naltrexone, calcein, insulin, and DNA vaccination (59-64). 
1.3.2. Novel approaches to enhance transdermal drug delivery 
 The two techniques that we have developed in our laboratory for efficient transdermal 
drug delivery are 
1. ChilDrive Iontophoresis 
2. Magnetophoresis  
ChilDrive iontophoresis is a technique of combining regional cutaneous hypothermia with 
iontophoresis for enhancing the transdermal delivery of drugs to deeper musculoskeletal tissues. 
Magnetophoresis is a technique of enhancing transdermal drug delivery by the application of 
magnetic field strength. 
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CHAPTER-2 
DERMAL DRUG LEVELS OF ANTIBIOTIC (CEPHALEXIN) DETERMINED BY 
ELECTROPORATION AND TRANSCUTANEOUS SAMPLING (ETS) TECHNIQUE 
 
2.1. ABSTRACT 
The purpose of this project was to assess the validity of a novel electroporation and 
transcutaneous sampling (ETS) technique for sampling cephalexin from the dermal extracellular 
fluid (ECF). This work also investigated the plausibility of using cephalexin levels in the dermal 
ECF as a surrogate for the drug levels in the synovial fluid. In vitro and in vivo studies were 
carried out using hairless rats to assess the workability of ETS. Cephalexin (20 mg/kg) was 
administered (i.v.) through tail vein and the time course of drug concentration in the plasma was 
determined. In the same rats, cephalexin concentration in the dermal ECF was determined by 
ETS and microdialysis techniques. In a separate set of rats, only intraarticular microdialysis was 
carried out to determine the time course of cephalexin concentration in the synovial fluid. The 
drug concentration in the dermal ECF determined by ETS and microdialysis did not differ 
significantly from each other and so as were the pharmacokinetic parameters. The results provide 
validity to the ETS technique. Further, there was a good correlation (~0.9) between synovial 
fluid and dermal ECF levels of cephalexin indicating that dermal ECF levels could be used as a 
potential surrogate for cephalexin concentration in the synovial fluid. 
Keywords: Electroporation; Transcutaneous sampling; Microdialysis; Pharmacokinetics.
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2.2. OBJECTIVES AND SIGNIFICANCE 
The objectives of this study are: 
I. To determine if ETS could be utilized for sampling of cephalexin from dermal ECF. 
II. To ascertain if the dermal ECF levels can serve as a surrogate for synovial fluid levels of 
cephalexin. 
The most commonly occurring infections in people are skin infections. Particularly, children and 
elderly people are mostly affected with skin infections due to lack of potent immune system. 
Cephalosporins are most widely used for treatment of skin infections because of their safety 
profiles (65-67). Cephalexin, a first generation cephalosporin antibiotic is mostly used because of 
its activity against both the gram-positive and gram-negative microorganisms (68). In addition to 
treatment of skin infections, cephalexin is also commonly used to treat the articular infections 
(69, 70). Achieving therapeutically active drug levels at the site of infection is vital for any 
antibiotic therapy. In general, when the infection is situated in the central pharmacokinetic 
compartment, the activity of the drug is determined by the unbound drug concentration in the 
plasma. However, in case of infections in the peripheral tissues such as skin and articular region, 
it is the time course of concentration of unbound antibiotic in the respective tissue fluids, which 
is crucial for successful treatment. In such cases monitoring the drug levels in the plasma may 
not reflect the actual levels in the affected tissue. Therefore, the time course of antibiotics in the 
affected tissue needs to be monitored for determining the frequency and dose of drug 
administration from the safety and efficacy perspectives of the antibiotic therapy (71-75). 
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2.3. MATERIALS AND METHODS 
2.3.1. Chemicals 
Cephalexin hydrate was purchased from Sigma-Aldrich Inc. (St. Louis, MO), Phosphate 
buffered saline (PBS, pH 7.4) premixed powder was obtained from EMD Chemicals 
(Gibbstown, NJ), and all other chemicals were obtained from Fischer Scientific (Fairway, NJ). 
2.3.2. In vitro experimental setup 
 The in vitro diffusion studies were carried out in Franz diffusion cells (FDC) (Logan 
Instruments Ltd., Somerset, NJ) using hairless rat skin excised from the abdomen region. 
Hairless rat skin is known to be a good model for topical and transdermal drug delivery studies 
due to the similarity between the rat and human skin with respect to lipid content and water 
uptake properties (76). Moreover, a good correlation of permeation data between the hairless rat 
model and human skin models has been reported by several research groups in the past (77). The 
skin was mounted on the diffusion cell in such a way that the epidermis side of the skin was in 
contact with upper sampling compartment and dermal side with the lower reservoir 
compartment. The active diffusion area of FDC was 0.64 cm2. Ag/AgCl electrode wires of 0.5 
mm diameter (Alfa Aesar, Ward Hill, MA) made in form of circular rings were placed 2 mm 
away from skin in both sampling and reservoir compartments. The sampling and the reservoir 
compartments were filled with 0.4 and 5 ml PBS respectively and the skin was allowed to 
equilibrate for 1 h. The AC electrical resistance of the epidermis was measured by placing a load 
resistor RL (100 kΩ) in series with the epidermis. The voltage drop across the whole circuit (VO) 
and across the skin (VS) was measured using an electrical set up consisting of a waveform 
generator and a digital multimeter (Agilent Technologies, Santa Clara, CA). For measuring 
12 
 
resistance, voltage of 100 mV was applied at 10 Hz and the skin resistance in kΩ was 
approximated from the formula: 
SO
LS
VV
RV
Rs
−
=
 (1) 
where RS is the skin resistance and RL is the load resistor in kΩ. The piece of skin which had a 
resistance greater than 20 kΩ.cm2 was used for the experiment.  
2.3.3. In vitro transcutaneous sampling studies 
The sampling compartment was replaced with 0.4 ml of PBS (pH 7.4) and the reservoir 
compartment was filled with 5 ml of cephalexin solution prepared in PBS (5-40 µg/ml). Thirty 
square electrical pulses each of 10 ms duration at 120 V/cm2, 1 Hz was applied using ECM 830 
Electro Square Porator (BTX Harvard apparatus, Holliston, MA). The electrical resistance was 
measured immediately after application of electrical pulses to ensure skin permeabilization. PBS 
from the sampling compartment was withdrawn 15 min after application of electrical pulses and 
the amount of cephalexin sampled was analyzed by HPLC. 
2.3.4. Ex vivo plasma protein binding  
The blood was collected by cardiac puncture in rats and the plasma was separated by 
centrifugation at 2000g at 4 ºC. Rat plasma was spiked with drug to provide concentration 
ranging from 1-20 µg/ml. The spiked plasma samples were thoroughly mixed by vortexing and 
allowed to equilibrate for 12 h at 4 ºC. After equilibration, protein free plasma was obtained by 
using ultra filtration (Millipore Centrifree® filtration units) by centrifugation of 0.5 ml of plasma 
at 2000g for 20 min (71, 76). The amount of unbound drug present in the filtrate was measured 
by HPLC after suitable dilution with PBS. 
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2.3.5. In vivo studies 
 The in vivo experimental procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Mississippi (Protocol#07-004). The in vivo studies 
were carried out in hairless rats (Taconic, Hudson, Newyork) (250-300 g) under ketamine (80 
mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally.  
Plasma sampling, ETS and microdialysis sampling was carried out in the same group of rats 
(n=6). The samples by all three procedures were obtained at the same time points in each rat 
simultaneously. Cephalexin solution of 20 mg/kg prepared in sterile isotonic saline was 
administered by i.v. into tail vein as a bolus injection. 
2.3.5.1. Cutaneous microdialysis 
A 20G needle was inserted intradermally through a distance of 1 cm and a linear 
microdialysis probe of 5 mm membrane length and 30 kDa cutoff molecular weight (BASi, West 
Lafayette IN) was inserted through this needle and the needle was withdrawn leaving the probe 
implanted in the dermal tissue. The inlet tube was connected to an injection pump (BASi, West 
Lafayette, IN) and PBS was perfused at 2 µl/min flow rate for 30 minutes for equilibration. Two 
samples were collected before drug administration. The drug was injected by i.v through the tail 
vein after equilibration of the probe. Subsequently, the microdialysis samples were collected 
continuously at every 15 minutes interval including at time points corresponding to ETS and 
plasma sampling at 30, 60, 120, 180, 240, 300 and 360 min. 
2.3.5.2. Electroporation and transcutaneous sampling  
 Prior to the drug administration, a custom made sampling cell was fixed using an 
adhesive (Krazy glue, Elmers products Inc, Ohio) on the back of the rats (Figure 2-1). The 
sampling cell was fitted with an Ag/AgCl electrode and the counter electrode was secured just 
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adjacent to the cell on the surface of the skin using a micropore surgical tape (3M Healthcare, 
MN).  
 
Figure 2-1. Diagrammatic representation showing an experimental setup of electroporation and 
transcutaneous sampling in hairless rats. 
 
The skin was hydrated with 100 µl of saline for 5 min before each sampling and was replaced 
with 100 µl of PBS (sampling buffer). One blank sample was collected before drug 
administration, and subsequent samples were collected at (30, 60, 120, 180, 240, 300 and 360 
min). For ETS procedure, 30 electrical pulses each of 10 ms duration at 120 V/cm2, 1 Hz was 
applied and the sampling fluid remained in the chamber for 15 min after pulsing.  
2.3.5.3. Plasma pharmacokinetics of drug 
 For plasma pharmacokinetic studies, 100 µl of blood was collected by retro-orbital 
bleeding before injection of drug and before each episode of transcutaneous sampling and 
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cutaneous microdialysis. The blood samples were diluted with 200 µl of PBS and plasma was 
separated followed by protein precipitation and the plasma drug content was analyzed by HPLC. 
2.3.5.4. Intraarticular microdialysis 
In another set of rats (n=6), intraarticular microdialysis was carried out to determine the 
amount of cephalexin present in the synovial fluid. After anaesthetizing the rats, the hind limb 
was held in a fixed position and a 20G needle was passed through the knee joint capsule lateral 
to the patellar ligament and a linear microdialysis probe of 5 mm length and 30 kDa cut off 
molecular weight (BASi, West Lafayette, IN) was inserted through the needle (78, 79). The 
needle was withdrawn leaving the probe implanted in the synovial cavity. PBS was perfused for 
30 min prior to drug administration for equilibration at flow rate of 2 µl/min. Cephalexin 
solution (20 mg/kg) was administered through the tail vein and microdialysis perfusion was 
continued for 6 h with samples collected for 15 min interval including at time points 
corresponding to ETS and cutaneous microdialysis sampling. 
In case of both cutaneous and intraarticular microdialysis, the probe recovery was determined in 
vivo by using retrodialysis method (80-82). For this, the probe was first equilibrated by perfusing 
PBS at 2 µl/min for 30 min; followed by drug solution of known concentration for 30 min. After 
equilibration, dialysate was collected for 15 min interval at 15, 30 and 45 min and the average 
recovery of three time points was considered. The in vivo recovery rate was calculated using the 
formula: 
Recovery %=100- Concentration of dialysate
Concentration of perfusate
 X 100                 (2) 
 
 
16 
 
2.3.6. Analytical method 
The amount of cephalexin present in plasma, ETS and microdialysis samples were 
analyzed by HPLC using Symmetry® C18 column (4.6 x 150 mm) with UV detection at 254 nm. 
Mobile phase consisted of a mixture of methanol and 2.5 mM sodium phosphate buffer, pH 5.6 
(20:80 v/v) and the flow rate was 1 ml/min. The sensitivity of the method was 10 ng/ml and 
linearity was between 10-1000 ng/ml (R2=0.99). To the plasma samples, equal volume of 
acetonitrile was added to precipitate proteins and then centrifuged at 2000g for 10 min at room 
temperature and the supernatant was analyzed for drug content (83, 84). ETS and microdialysis 
samples were centrifuged and directly injected into HPLC system. 
2.3.7. Data Analysis  
The plasma pharmacokinetic parameters were calculated based on two compartment 
model represented by the equation: 
C = Ae-αt + Be-βt                                                 (3)               
 where A, B are the pre-exponential constants, α is the distribution rate constant, β is the 
elimination rate constant. The values of α, β, A and B are derived from curve fitting of 
experimental data. The elimination half life (t1/2) was calculated using the formula 0.693/β and 
area under the curve (AUC0-6h) was calculated using the trapezoid rule. The pharmacokinetic 
parameters in case of dermal ECF and synovial fluid were calculated using non compartmental 
pharmacokinetic model. 
The statistical analysis was carried out using GraphPad Instat 3 software and the unpaired t-test 
was selected for comparing the parameters obtained from ETS and microdialysis techniques. 
P<0.05 was considered as level of significance. From Pearsons correlation, R2 and P-value were 
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calculated using Pearson Correlation (v1.0.3) in Free Statistics Software (v1.1.23-r1). The data 
points shown in graphs are an average of 6 trials with error bars representing standard deviation. 
2.4. RESULTS AND DISCUSSION 
Calibration of ETS was carried out in vitro using freshly excised hairless rat skin model. 
Known concentrations of drug were placed in the reservoir compartment and the drug was 
sampled following electroporation. The amount of drug diffused in 15 min following application 
of electrical pulses was plotted against respective reservoir concentrations (5-40 µg/ml) as 
represented in Figure 2-2. 
The linear relationship (R2=0.96) between the amount of drug sampled and the reservoir drug 
concentration implies that the ETS samples would potentially represent the subdermal drug 
concentration. The percentage recovery by ETS can be obtained by (slope X 100) from Figure 2-
2 and was found to be 3.06±0.2%.  In control (across the untreated skin) the amount of drug 
sampled was less than detectable levels. In case of electroporation trials, the resistance of skin 
dropped ~74±8% whereas in case of control set of experiments, electrical resistance of skin did 
not change significantly. The recovery of electrical resistance of electroporated skin was 
insignificant within the sampling duration of 15 min, which is in agreement with previous reports 
in case of ETS across the rat skin and porcine epidermis (74, 85). 
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Figure 2-2. Correlation between cephalexin concentration (5-40 µg/ml) in the reservoir 
compartment and cephalexin sampled by ETS across hairless rat skin in vitro (y=0.03x, 
R2=0.96). 
 
The plasma protein binding of cephalexin revealed that the fraction of cephalexin bound to 
plasma was 10.2±2.6% at concentrations between 1-20 µg/ml. Low protein binding of 
cephalexin is considered to be one of the major reasons for its extensive distribution into the 
peripheral tissues. The protein binding values were in agreement with 12.4% that was reported 
by Tsai et al (68). 
The concentration time profile of cephalexin in plasma and dermal extracellular fluid 
(determined by ETS and cutaneous microdialysis) samples following i.v. administration of 
cephalexin (20 mg/kg) is shown in Figure 2-3.  
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Figure 2-3. Time course of cephalexin in rat plasma (●) determined by blood sampling and 
dermal ECF determined by microdialysis (■) and ETS (▲) tecniques following i.v. bolus 
administration of 20 mg/kg of cephalexin. 
 
The plasma concentration versus time data of cephalexin could be described by a two 
compartment model (86). The pharmacokinetic parameters calculated for plasma drug 
concentration-time profile are given in Table 2-1. The plasma drug concentrations reported in 
this project are comparable to that reported by Tsai et al in rats considering the difference in dose 
between the two studies. The plasma elimination half life of cephalexin in the current study was 
104.59±28.61 min (1.74±0.47 h) which agrees well with the elimination half life (1.4±0.81 h) 
reported by Padoin et al (68, 86). 
 
0
5
10
15
20
25
30
0 60 120 180 240 300 360
C
ep
ha
le
x
in
 
co
n
ce
n
tr
a
tio
n
 
(µ
g/
m
l)
Time (min)
20 
 
Table 2-1. Pharmacokinetic parameters derived from the plasma concentration-time data after i.v 
bolus administration of 20 mg/kg of cephalexin in hairless rats. 
 
Parameter i.v. bolus 
A (µg/ml) 52.35±1.41 
B (µg/ml) 11.89±1.04 
t1/2 (min) 104.59±28.61 
α (1/min) 0.03355±0.004 
β (1/min) 0.00688±0.001 
AUC0-6h (µg.min/ml) 3160.93±250.35 
 
The recovery of cephalexin by the microdialysis probe in the cutaneous tissue was found to be 
21.14±5.26% whereas the recovery of cephalexin by ETS was only about 3.06±0.2% which is 
about 7-fold less than that of microdialysis. Although ETS has the advantage of being 
noninvasive as opposed to microdialysis, the later has the limitation with the amount of drug that 
could be sampled from the dermal ECF. Nevertheless, recovery could likely be improved by 
using more vigorous electrical protocol and/or by increasing the sampling duration. In both 
microdialysis as well as  ETS techniques,  the amount of cephalexin present in the dermal ECF in 
rats was calculated using the amount sampled and the corresponding recovery values as follows. 
Dermal ECF concentration= sample concentration
percentage recovery
                  (4) 
In the current study, the point to point comparison of the drug concentration in the dermal 
extracellular fluid and the pharmacokinetic parameters, i.e. Cmax, Tmax, AUC0-6h and t1/2, 
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determined by ETS and microdialysis techniques did not differ significantly (unpaired t-test, 
P<0.05) (Table 2-2). This provides validity to the ETS technique of sampling cephalexin.  
Table 2-2. Mean pharmacokinetic parameters of cephalexin determined by ETS, microdialysis 
techniques following administration of 20 mg/kg by i.v bolus in hairless rats. 
Parameter ETS Microdialysis P-value 
Tmax (min) 120 120 -- 
Cmax (µg/ml) 13.09±1.92 12.64±1.90 0.39 
AUC0-6h(µg.min/ml) 2512.35±250.14 2473.66±202.43 0.42 
t1/2 (min) 106.61±17.81 96.37±12.33 0.22 
 
The amount of drug present in the synovial fluid is shown in Figure 2-4 and the pharmacokinetic 
parameters are given in Table 2-3. In this case, the in vivo microdialysis probe recovery was 
found to be 10.64±3.44%. The Cmax in case of synovial fluid (3.23±0.58 µg/ml) was four fold 
less than the dermal ECF (~13.09 µg/ml). This data suggests that relatively higher doses of 
cephalexin would be required to achieve effective drug levels in the synovial fluid.     
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Figure 2-4. Concentration-time profile of cephalexin in synovial fluid obtained by intraarticular 
microdialysis after administration of 20 mg/kg of drug by i.v. bolus. 
 
Table 2-3. Mean pharmacokinetic parameters of cephalexin determined by intraarticular 
microdialysis in the synovial fluid following administration of 20 mg/kg by i.v bolus in hairless 
rats. 
 
Parameter Synovial fluid 
Tmax (min) 120 
Cmax (µg/ml) 3.233±0.58 
t1/2 (min) 96.215±8.08 
AUC0-6h (µg.min/ml) 654.10±101.35 
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The drug levels from synovial fluid were plotted against drug levels in dermal ECF obtained by 
ETS and microdialysis techniques. A good correlation of 0.92 (P=0.00029) and 0.91 
(P=0.00047) was observed between the drug levels in synovial fluid and dermal ECF obtained 
from ETS (Figure 2-5) and microdialysis (Figure 2-6). 
 
 
Figure 2-5. Correlation between cephalexin levels in dermal ECF obtained from ETS with that 
of synovial fluid drug levels (y=3.78x, R2=0.92). 
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Figure 2-6. Correlation between cephalexin levels in dermal ECF obtained from microdialysis 
with that of synovial fluid drug levels (y=3.72x, R2=0.91). 
From this relationship, it could be said that in rats, the drug level in the skin represents ~3.7X of 
that in the synovial fluid. Establishing such correlation between the dermal ECF and the 
concentration of drug in internal tissues would help in monitoring the drug levels of peripheral 
tissues which are extremely difficult to access. From the results of this experiment it appears that 
dermal ECF levels of cephalexin could be used as potential surrogate for cephalexin levels in the 
synovial fluid. 
ETS is a noninvasive method of cutaneous drug sampling and is expected to be relatively safer 
than microdialysis method. However, there are concerns about potential skin damage due to the 
application of electrical pulses. Many research groups have evaluated the safety of skin 
electroporation in animal models and human subjects. Vanbever et al. have reported that 
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reversible mild skin reactions occurred following the application of 15 electrical pulses of 250 V 
and 200 ms in vivo in hairless rats (87). Wong et al. have shown that electroporation can be 
carried out in humans without causing pain at 150 V, 1 ms, 60 pulses by using microelectrode 
array (88). The protocol that was applied in current experiments was 120 V, 30 square pulses 
each of 10 ms duration which is rather mild than the protocols applied on human subjects in 
other studies. The extent of skin damage depends on the applied electrical protocol and the 
electrode design. Therefore the optimum electrical protocols need to be evaluated in vivo for 
tolerability, morphological, histological, and biochemical changes in the skin before 
implementation in clinical practice. 
2.5. CONCLUSIONS 
 ETS is a potential noninvasive technique that could be developed for sampling of drugs 
from the skin tissue. However, the major limitation of the technique is low recovery, which 
limits the application of the technique to drugs which are less protein bound and which are 
present considerably in high amounts in the dermal ECF. One of the most interesting outcomes 
of the present work was that the dermal ECF concentration of cephalexin correlated well with the 
concentration in synovial fluid. 
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CHAPTER-3 
TRANSCUTANEOUS SAMPLING OF CIPROFLOXACIN AND  
8-METHOXYPSORALEN BY ELECTROPORATION (ETS TECHNIQUE) 
 
3.1. ABSTRACT 
The novel technique of transcutaneous sampling of drugs by electroporation was 
developed to study the dermatokinetics of ciprofloxacin and 8-methoxypsoralen. The selected 
drugs differ in their aqueous solubility and also with respect to the extent of protein binding. 
Ciprofloxacin (15 mg/kg) was administered i.v. through tail vein whereas 8-methoxypsoralen (5 
mg/kg) was given by oral administration in hairless rats and the time course of drug 
concentration in the plasma was determined. Drug concentration in the dermal extracellular fluid 
(ECF) was determined by ETS and microdialysis sampling techniques. The drug concentration in 
the dermal ECF determined by ETS and microdialysis did not differ significantly from each 
other and so as were the pharmacokinetic parameters. The results show that ETS can be utilized 
as a potential technique for sampling of drugs from the dermal extracellular fluid. 
Keywords: Electroporation; Transcutaneous sampling; Hairless rats; Microdialysis; 
Pharmacokinetics; Extracellular fluid.  
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3.2. OBJECTIVES AND SIGNIFICANCE 
The objectives of the study are: 
I. To assess the feasibility of ETS technique for drugs of different physicochemical 
properties. 
II. To assess the workability of ETS technique, when drugs are administered via different 
routes.  
Two drugs ciprofloxacin and 8-methoxypsoralen which possess different physicochemical 
properties and also differ in their extents of protein binding are selected as model drugs. For the 
purpose of assessing the validity of the technique, the two drugs were administered by different 
routes in this project (Ciprofloxacin by i.v. bolus and 8-methoxypsoralen by oral route).  
Ciprofloxacin, a broad spectrum antibacterial agent belonging to the group of fluoroquinolones is 
effective against microbial infections localized in the skin. The time course of ciprofloxacin in 
the skin needs to be monitored for determination of the frequency and dose from safety and 
efficacy perspectives (71, 89-91). 
8-methoxypsoralen, a furocoumarinic is used in conjunction with UV radiation (PUVA therapy) 
for the treatment of dermatoses like vitilgo and psoriasis (92-94). The effectiveness of 8-
methoxypsoralen depends on ultraviolet-A irradiation and optimum response will be elicited 
only when the drug concentration in skin is over the effective concentration. For this reason, it is 
imperative to determine drug concentration in skin to achieve better PUVA therapy (95-97). 
3.3. MATERIALS AND METHODS 
3.3.1. Chemicals 
Ciprofloxacin Hydrochloride, 8-Methoxypsoralen were purchased from Sigma-Aldrich 
Inc (St.Louis, MO), Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained 
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from EMD Chemicals (Gibbstown, NJ), and all other chemicals were obtained from Fischer 
Scientific (Fairway, NJ). 
3.3.2. In vitro transcutaneous sampling studies 
The in vitro diffusion studies were carried out in Franz diffusion cells (FDC) (Logan 
Instruments Ltd., Somerset, NJ) using hairless rat skin excised from the abdomen region. 
Hairless rat skin is considered to be a good model for topical and transdermal drug delivery 
studies due to the similarity between the rat and human skin with respect to lipid content and 
water uptake properties (76). Moreover, a good correlation of permeation data between the 
hairless rat model and human skin models have been reported by several research groups in the 
past (77). The skin was mounted on the diffusion cell in such a way that the epidermis side of the 
skin was in contact with upper sampling compartment and dermal side with the lower reservoir 
compartment. The active diffusion area of FDC was 0.64 cm2. Ag/AgCl electrode wires of 
0.5 mm diameter (Alfa Aesar, Ward Hill, MA) made in the form of circular rings were placed 
2 mm away from skin in both sampling and reservoir compartments. The sampling compartment 
and the reservoir compartment were filled with 0.4 and 5 ml PBS, respectively and the skin was 
allowed to equilibrate for an hour. The AC electrical resistance of the epidermis was measured 
by placing a load resistor RL (100 kΩ) in series with the epidermis. The voltage drop across the 
whole circuit (VO) and across the skin (VS) was measured using an electrical set up consisting of 
a waveform generator and a digital multimeter (Agilent Technologies, Santa Clara, CA). For 
measuring resistance, voltage of 100 mv was applied at 10 Hz and the skin resistance in kΩ was 
approximated. The piece of skin, which had a resistance greater than 20 kΩ.cm2 was used for the 
experiment. 
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Later, the sampling compartment was replaced with fresh 0.4 ml of PBS and reservoir 
compartment was filled with 5 ml of ciprofloxacin solution prepared in PBS (2.5-40 µg/ml). In 
case of 8-methoxypsoralen, the sampling compartment was replaced with PBS:ethanol (50:50) 
and the reservoir compartment was filled with 5 ml of 8-methoxypsoralen solution (2.5-
40 µg/ml) prepared in PBS:ethanol (50:50). Thirty square electrical pulses each of 10 ms 
duration at 120 V/cm2, 1 Hz was applied using ECM 830 Electro Square Porator (BTX Harvard 
apparatus, Holliston, USA). The electrical resistance of the skin was measured immediately after 
application of the electrical pulses to ensure skin permeabilization. The solution from the 
sampling compartment was withdrawn 15 min after application of electrical pulses and the 
amount of drug was analyzed by HPLC. 
3.3.3. Ex vivo plasma protein binding 
 The blood was collected by cardiac puncture in rats and the plasma was separated by 
centrifugation at 2000g at 4 °C. Rat plasma was spiked with drug to prepare samples of 
concentration ranging from 1 to 40 µg/ml. The spiked plasma samples were thoroughly mixed by 
vortexing and allowed to equilibrate for 12 h at 4 °C. After equilibration, protein free plasma was 
obtained by carrying out ultra filtration (Millipore Centrifree® filtration units) by centrifugation 
of 0.5 ml of plasma at 2000g for 20 min. The amount of unbound drug present in the filtrate was 
measured by HPLC after suitable dilution with PBS (74, 98). 
3.3.4. In vivo studies 
 The in vivo experimental procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Mississippi (Protocol#07-004). The in vivo studies 
were carried out in hairless rats (Taconic, Hudson, Newyork) (250-300 g) under ketamine (80 
mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally.  
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Blood sampling, ETS and microdialysis sampling was carried out in the same group of rats 
(n=6).The samples by all three procedures were obtained at the same time points in each rat 
simultaneously. Ciprofloxacin solution (150-180 µl) of 15 mg/kg prepared in sterile isotonic 
saline was administered by i.v. into tail vein as a bolus injection, whereas in case of 8-
methoxypsoralen, solution (415-500 µl) of 5 mg/kg prepared in 50:50 of PBS:ethanol was given 
by oral gavage using a ball ended feeding needle. 
3.3.4.1. Cutaneous microdialysis 
 For cutaneous microdialysis, a 20G needle was inserted intradermally through a distance 
of 1 cm and penetration depth of 2 mm. A linear microdialysis probe of 5 mm membrane length 
and 30 kDa cutoff molecular weight (BASi, West Lafayette IN) was inserted through this needle 
and the needle was withdrawn leaving the probe implanted in the dermal tissue. The proper 
placement of probe in the dermis was confirmed by making an incision at the site of probe 
implantation after completion of the study. Any experiment, in which the probe was not placed 
horizontally at the intended depth was not considered. 
The inlet tube was connected to an injection pump (BASi, West Lafayette, IN) and perfusion was 
set to a flow rate of 2 µl/min. The probe was equilibrated for 30 min (99-101). The perfusate was 
PBS for studies involving ciprofloxacin and PBS:ethanol (50:50) for 8-methoxypsoralen. Two 
samples were collected before drug administration. The drug was administered after equilibration 
of the probe. Subsequently the microdialysis samples were collected continuously at every 15 
min interval including at time points corresponding to ETS and plasma sampling at 30, 60, 120, 
180, 240, 300 and 360 min. The microdialysis probe recovery was determined in vitro by placing 
microdialysis probe in PBS containing known drug concentration and perfusing the probe with 
PBS (for ciprofloxacin) and 50:50 PBS:ethanol (for 8-methoxypsoralen) at flow rate of 2 µl/min. 
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The dialysate coming out of the probe is collected every 15 min and analyzed for drug content 
(102, 103). The in vitro recovery rate was calculated using the formula: 
% Relative recovery= concentration of dialysate
concentration of sample
X 100     (5) 
3.3.4.2. Transcutaneous sampling by electroporation 
 A custom made sampling cell was fixed using an adhesive (Krazy glue, Elmers products 
Inc., Ohio) on the back of the rats. The sampling cell was fitted with a Ag/AgCl electrode and 
the counter electrode was secured just adjacent to the cell on the surface of the skin using a 
micropore surgical tape (3 M Healthcare, MN). The skin was hydrated with 100 µl of saline for 
5 min before each sampling and was replaced with 100 µl of sampling buffer (PBS for 
ciprofloxacin, PBS:ethanol (50:50) for 8-methoxypsoralen). One blank sample was collected 
before drug administration, and subsequent samples were collected at 30, 60, 120, 180, 240, 300 
and 360 min. For ETS procedure, thirty square electrical pulses each of 10 ms duration at 
120 V/cm2, 1 Hz was applied and the sampling fluid remained in the chamber for 15 min after 
pulsing. 
3.3.4.3. Plasma pharmacokinetics of drugs 
 For plasma pharmacokinetic studies, 100 µl of blood was collected by retro-orbital 
bleeding before administration of drug and before each episode of transcutaneous sampling and 
cutaneous microdialysis. The blood samples were diluted with 200 µl of PBS and plasma was 
separated by centrifugation at 2000g. In case of ciprofloxacin, plasma samples were subjected to 
protein precipitation with equal volume of 0.5 M perchloric acid, followed by centrifugation at 
10000g for 10 min and drug content was analyzed by HPLC (90). 8-methoxypsoralen in the 
plasma was extracted with methylene chloride for 30 min followed by centrifugation at 5000g at 
4 ○C for 10 min, the organic phase was separated and evaporated to dryness at room temperature 
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under nitrogen and the residue was dissolved in PBS:ethanol (50:50) and analyzed by HPLC 
(104). 
3.3.5. Analytical method 
The amounts of ciprofloxacin and 8-methoxypsoralen present in plasma, ETS and 
microdialysis samples were analyzed by high performance liquid chromatography. The HPLC 
system (Waters, MA) consisted of a chromatographic pump (Waters 1525) and an autosampler 
(Waters 717 plus).  
Analysis of ciprofloxacin samples were carried out using a fluorescence detector (Waters 2475) 
at an excitation wavelength of 278 nm and emission wavelength of 445 nm. Symmetry® C18 
column (4.6 x 150 mm) was used and the mobile phase consisted of a mixture of acetonitrile and 
0.1 M aqueous monopotassium phosphate solution adjusted to pH 2.5 with orthophosphoric acid 
(15:85 v/v) with flow rate of 2 ml/min (90). The linearity range was between 1-1000 ng/ml 
(R2=0.99). 
Analysis of 8-methoxypsoralen samples were carried out using a UV detector (Waters 2487) at 
248 nm using Symmetry® C18 column (4.6 x 150mm). The mobile phase consisted of a mixture 
of methanol, acetonitrile and water (2:30:68) and the flow rate was 1ml/min (104, 105). 
3.3.6. Data analysis 
The pharmacokinetic parameters were calculated using non compartmental 
pharmacokinetic model. The terminal elimination rate constant (λz) was determined from the 
slope of terminal exponential phase of the logarithmic plasma concentration-time curve. The 
elimination half life (t1/2) was calculated using 0.693/λz .The area under the curve (AUC0-t) was 
caclulated using the trapezoidal rule and AUC0-∞ was obtained by adding Clast/λz to AUC0-t. In 
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case of  8-methoxypsoralen, the maximum plasma concentration (Cmax ) and the time to reach 
maximum plasma concentration (Tmax ) were determined from the concentration-time curves. 
The statistical analysis was carried out using GraphPad Instat 3 software and the t-test was 
selected for comparing the parameters obtained from ETS and microdialysis techniques. P<0.05 
was considered as level of significance. The data points shown in graphs are an average of 6 
trials with error bars representing standard deviation. 
3.4. RESULTS AND DISCUSSION 
Solubility of drug in the sampling fluid is one of the key determinants of recovery of drug 
in case of both ETS and microdialysis. PBS was found to be an appropriate solvent for sampling 
ciprofloxacin. However, in the case of 8-methoxypsoralen, the recovery was poor with PBS 
which was likely due to the low water solubility of 8-methoxypsoralen (water solubility of 8-
methoxypsoralen is ~55.8 µg/ml). The recovery of 8-methoxypsoralen was improved with 50:50 
PBS:ethanol system in both ETS and microdialysis techniques.  
Electroporation leading to permeabilization of the skin is indicated by the drastic drop in 
electrical resistance of the skin. The drop in electrical resistance has been reported to be due to 
formation of transient aqueous pathways in the lipid domain of the stratum corneum. The 
aqueous pathways reseal and the skin will regain its barrier property  (thus its original electrical 
resistance). The extent of drop in electrical resistance and the duration required for  the skin to 
recover is determined by the applied electrical protocol. With the protocol of 120 V, 10 ms, 30 
pulses applied in this project, the drop in skin resistance was ~70±5%. There was no significant 
recovery in skin resistance during the sampling time of 15 min. However, the skin resistance 
recovered within few hours reflecting the fact that the electrical protocol was not too aggressive 
to bring about irreversible impairment of the skin barrier. This was in agreement with the 
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observations in previous studies carried out across the rat skin and porcine epidermis (35, 74, 
85). 
Transcutaneous sampling was also carried out across the untreated skin (did not apply electrical 
pulses) which served as control set of experiment. In case of untreated skin (control samples), 
detectable level of drugs could not be sampled within the sampling duration of 15 min. In case of 
ETS, detectable amounts of drug was sampled even at low reservoir drug concentrations. The 
amount of drug sampled in 15 min following application of electrical pulses was plotted against 
the corresponding reservoir drug concentrations (Figure 3-1 and 3-2).  
 
Figure 3-1. Correlation between ciprofloxacin concentration (2.5-40 µg/ml) in the reservoir 
compartment and the amount sampled by ETS across hairless rat skin in vitro (y=0.048x, 
R2=0.96). 
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A linear relationship (R2=0.96 and 0.98 for ciprofloxacin and 8-methoxypsoralen respectively) 
was observed between the amount of drug sampled and the reservoir drug concentration, 
indicating that the subdermal drug concentration can be represented by ETS samples. The 
percentage recovery by ETS (slope X 100) was 4.8±0.8% and 7.6±1.3% for ciprofloxacin and 8-
methoxypsoralen respectively. The recovery of 8-methoxypsoralen was less (~0.5%)  when ETS 
was carried out with PBS alone.      
 
 
Figure 3-2. Correlation between 8-methoxypsoralen concentration (2.5-40 µg/ml) in the 
reservoir compartment and the amount sampled by ETS across hairless rat skin in vitro 
(y=0.076x, R2=0.98). 
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by the plasma protein binding. Generally, the drugs that show high protein binding penetrate less 
into the peripheral compartment. Ex vivo plasma protein binding studies were carried out for 
both ciprofloxacin and 8-methoxypsoralen to assess the relationship between the protein binding 
and tissue penetration. The plasma protein binding of ciprofloxacin was found to be 
20.65±3.93% at concentrations between 1-40 µg/ml which was in aggreement with 16-40% 
reported by other research groups (106-108). The fraction of 8-methoxypsoralen bound to 
plasma was 80.97±6.85%. This was comparable to 91.4% reported by Pibouin et al (109). The 
two drugs chosen for this project differ significantly with respect to their protein binding 
property. One of the major objectives of this project was to assess the workability of the ETS 
technique in case of drugs which exhibit different extents of protein binding. 
The in vitro recovery of ciprofloxacin and 8-methoxypsoralen by microdialysis probe  were 
found to 3.47±0.35% and 16.41±3.32% respectively. Generally microdialysis is regarded as less 
suitable for sampling lipophilic drugs because, microdialysis method of drug sampling involves 
perfusion of aqueous sampling fluid through the dialysis probe during which the exchange of 
ingredients between the perfusion fluid and tissue fluid takes place. The perfusate liquids are 
preferably aqueous and therefore when the drug to be sampled is highly lipophilic, the recovery 
of the drug with the aqueous perfusion liquids would be relatively very less (101, 110, 111). It is 
not recommended to use organic solvents as the perfusate could alter the dialysis membrane 
properties and may also cause potential toxicity to the tissue. However, in this study, we found 
that the permeability of the dialysis membrane did not change significantly even after immersing 
the membrane for over 24 hours in the 50:50 PBS:ethanol system.   
In case of ETS, as the technique is noninvasive and the sampling fluid is in contact with the 
tissue for a short period of time during drug sampling, use of hydroalcoholic systems pose 
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relatively less severe risk as compared to microdialysis. This shows that ETS technique could be 
used to sample even lipophilic drugs, by changing the  the sampling fluid constitution 
appropriately. This is considered as one of the the advantages of ETS over microdialysis 
technique. 
In the current experiments, as the animals were anesthetized, there were no notable irritation 
symptoms due to electroporation or microdialysis. There was no inflammation due to application 
of electrical pulses or insertion of probe. However, there was slight bleeding during the 
implantation of the probe which stopped within 1 or 2 min completely. 
From both microdialysis and ETS techniques, the amount of ciprofloxacin and 8-
methoxypsoralen present in the dermal ECF in rats was calculated using the amount sampled and 
the corresponding recovery values as follows: 
Dermal ECF concentration= sample concentration
percentage recovery
       (6) 
The concentration time profile of ciprofloxacin (15 mg/kg) in plasma and dermal ECF 
(determined by ETS and cutaneous microdialysis) following i.v. bolus administration was 
represented in Figure 3-3. The pharmacokinetic parametes calculated from non-compartmental 
analysis are given in Table 3-1.  
The plasma elimination half life of ciprofloxacin in the present study was found to be 
124.12±25.99 min. This was comparable to 102.3±26.2 min and 91±8.6 min reported by 
Nouaille-Degorce et al. and Tsai et al. respectively (91, 106). 
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Figure 3-3. Time course of ciprofloxacin in rat plasma (●-total drug; ♦-unbound drug) 
determined by blood sampling and dermal ECF  determined by microdialysis (■) and ETS (▲) 
techniques following i.v. bolus administration of 15 mg/kg of ciprofloxacin. 
 
Table 3-1. Mean pharmacokinetic parameters of ciprofloxacin (unbound) in plasma and dermal 
ECF (determined by ETS and microdialysis) following administration of 15 mg/kg by i.v bolus 
in hairless rats. 
Parameter ETS Microdialysis Plasma 
Tmax (min) 30 30 30 
Cmax (µg/ml) 0.906±0.046 0.729±0.196 1.695±0.131 
AUC0-∞ (µg.min/ml) 88.29±20.41 89.71±25.18 240.33± 29.59 
t1/2 (min) 55.84±13.44 82.36±22.54 124.12±25.99 
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Figure 3-4 represents the concentration-time profile of 8-methoxypsoralen in plasma and dermal 
ECF (determined by ETS and cutaneous microdialysis) following oral administration of 5 mg/kg 
of 8-methoxypsoralen. The pharmacokinetic parametes calculated from non-compartmental 
analysis are given in Table 3-2. 
 
Figure 3-4. Time course of 8-methoxypsoralen in rat plasma (●-total drug; ♦-unbound drug) 
determined by blood sampling and dermal ECF determined by microdialysis (■) and ETS  (▲) 
technique following oral administration of 5 mg/kg of 8-methoxypsoralen. 
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mg/kg of 8-methoxypsoralen to rats, Cmax and Tmax were ~1.2 µg/ml and 150 min respectively 
(112). 
Table 3-2. Mean pharmacokinetic parameters of 8-methoxypsoralen (unbound) in plasma and 
dermal ECF (determined by ETS and microdialysis) following oral administration of 5 mg/kg in 
hairless rats. 
Parameter ETS Microdialysis Plasma 
Tmax (min) 120 120 120 
Cmax (µg/ml) 0.338 ± 0.080 0.280 ± 0.051 0.644 ± 0.142 
AUC0-∞ (µg.min/ml) 116.08 ± 29.22 116.10 ± 22.85 120.72 ± 36.25 
t1/2 (min) 243.83 ± 18.43 237.76 ± 15.83 97.15 ± 6.72 
 
The point to point comparison of the drug concentration in the dermal ECF and the 
dermatokinetic parameters, i.e. Cmax, Tmax, AUC0-∞ and t1/2 determined by ETS and microdialysis 
technique for ciprofloxacin and 8-methoxypsoralen did not differ significantly (t-test, P<0.05) 
(Table 3-1 and Table 3-2). This provides validity to the ETS technique for sampling drugs like 
ciprofloxacin and 8-methoxypsoralen. The study also demonstrates that ETS could be 
implemented in dermatokinetic investigation regardless of route of administration of drugs. 
Successful development of a sampling device based on the ETS concept would be very useful in 
carrying out dermatokinetic investigations of drugs. The noninvasiveness of the technique 
permits frequent sampling of drugs which helps in relatively more precise calculation of the 
kinetic parameters. In addition, the technique could be used to sample drugs in routine 
therapeutic drug monitoring. ETS is a potential technique for cutaneous sampling of drugs and 
analytes and could replace the invasive blood sampling procedure in future. 
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3.5. CONCLUSIONS 
The results of this project showed the workability of ETS in case of drugs with different 
solubility and different degree of protein binding. In addition, the present work also demonstrates 
the workability of the ETS technique in case of intravenous and oral routes of drug 
administration.  
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CHAPTER-4 
NONINVASIVE TRANSCUTANEOUS SAMPLING OF GLUCOSE BY 
ELECTROPORATION 
4.1. ABSTRACT 
Monitoring of blood glucose levels involves the invasive method of withdrawing blood 
which causes inconvenience to patients. The objective of this study was to investigate the 
efficiency of the noninvasive electroporation and transcutaneous sampling (ETS) technique for 
predicting blood glucose levels. In vitro studies were carried out in Franz diffusion cells using 
porcine epidermis to assess the feasibility of transcutaneous sampling of glucose. In vivo, the 
ETS technique was assessed in the diabetes-induced Sprague-Dawley rat model. Glucose was 
sampled following the application of 30 electrical pulses of 1 ms duration at 120 V/cm2, 1 Hz. 
Clarke error grid analysis was carried out for the venous blood glucose levels that were 
determined by the ETS with reference to those measured by a glucose meter. The amount of 
glucose sampled by the ETS method both in vitro and in vivo was proportional to the dermal 
glucose concentration. All data points from in vivo studies were in A and B zones of Clarke error 
grid analysis, and the mean absolute relative error was 12.8%. Results of the present study 
demonstrate that ETS technique could be developed as a noninvasive method of predicting 
venous blood glucose levels in people with diabetes. 
Keywords: Electroporation and transcutaneous sampling; Glucose; In vitro; In vivo 
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4.2. OBJECTIVES AND SIGNIFICANCE 
The objective of the study was to investigate the feasibility of utilizing ETS technique to 
sample glucose from dermal ECF that correlates with blood glucose levels. 
Diabetes mellitus is a major health concern. Diabetes can lead to chronic complications such as 
heart disease, blindness, renal failure, peripheral vascular disease, and limb amputation (113, 
114). For proper diabetes management, it is very important that blood glucose levels are checked 
regularly. This involves the invasive method of collecting blood through a finger stick system 
which has been a major inconvenience for patients (115). Some patients avoid glucose 
measurements due to needle phobia. To overcome this problem, different noninvasive blood 
glucose monitoring methods have been developed, including near-infrared spectroscopy, far-
infrared spectroscopy, radio wave impedance, reverse iontophoresis, ultrasound, blister 
technique, and microneedles (116-120). ETS technique involves application of a few short 
electrical pulses on the surface of the skin, which permeabilize the stratum corneum by creating 
transient aqueous pathways. The dermal glucose diffuses into the sampling fluid, which is in 
contact with the permeabilized region of the skin. 
4.3. MATERIALS AND METHODS 
4.3.1. Chemicals 
Glucose, alloxan monohydrate, and the glucose assay kit (GAHK-20) were purchased 
from Sigma-Aldrich Inc. (St. Louis, MO); 10X phosphate-buffered saline (PBS) premixed 
powder was obtained from EMD Chemicals (Gibbstown, NJ). 
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4.3.2. Skin 
Porcine belly skin was obtained from a local abattoir. Pieces of skin wrapped in 
aluminum foil were heated to 60 °C for 2 min, and the epidermis was gently peeled off the skin. 
The fresh epidermis was used for in vitro glucose sampling by electroporation. 
4.3.3. In vitro glucose sampling by electroporation 
In vitro diffusion studies were carried out in Franz diffusion cells (Logan Instruments 
Ltd., Somerset, NJ) using porcine epidermis. The stratum corneum side of the skin was in 
contact with the upper sampling compartment and the ventral side with the reservoir 
compartment. The active diffusion area was 0.64 cm2. Ag/AgCl electrode wires of 0.5 mm 
diameter (Alfa Aesar, Ward Hill, MA) made in the form of circular ring were placed 2 mm away 
from the skin in both the sampling and the reservoir compartments. The upper sampling 
compartment and the reservoir compartment were filled with 0.4 and 5 ml PBS respectively. The 
electrical resistance of the epidermis was measured by placing a load resistor RL (100 kΩ) in 
series with the epidermis. Voltage drop across the whole circuit (VO) and across the epidermis 
(VS) were measured using a multimeter (Agilent Technologies, Santa Clara, CA). The piece of 
porcine epidermis with a resistance greater than 20 kΩ.cm2 was used for the experiment.  
The upper sampling compartment was filled with 0.4 ml of PBS, pH 7.4, and the lower reservoir 
compartment was filled with 5 ml of glucose solution in PBS with concentrations between 50 
and 400 mg/dl. Electroporation was carried out using an ECM 830 Electro Square Porator (BTX 
Harvard Apparatus, Holliston, MA). The electroporation protocol was 30 pulses each of 1 ms 
duration at 120 V/cm2 of active diffusion area. PBS from the sampling compartment was 
withdrawn 15 min after the application of electrical pulses, and the amount of glucose was 
measured using the glucose assay kit by UV spectrophotometer at 340 nm. The in vitro 
permeability coefficient, Pin vitro (cm/min) was calculated using the formula: 
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Pin vitro =
Glucose flux in 15 min
 Glucose concentration in reservoir compartment
       (7) 
4.3.4. In vivo glucose sampling by electroporation 
The in vivo experimental procedures were approved by the Institutional Animal Care and 
Use Committee at the University of Mississippi (Protocol #07-028). In vivo studies were carried 
out in Sprague-Dawley rats (Harlan, Indianapolis, IN) (200–224 g) under ketamine (80 mg/kg) 
and xylazine (10 mg/kg) anesthesia. The moisture content in the epidermal layers and in the 
dermis of each rat was measured using the Delfin moisture meter-SC and the Delfin moisture 
meter-D (Delfin Technologies Ltd., Kuopio, Finland) before sampling to ensure the absence of 
edema or inflammation (121). 
Glucose sampling by ETS was carried out using a custom made sampling cell. The back portion 
of rats was shaved, and a custom-made in vivo electroporation cell was fixed using an adhesive 
(Krazy Glue, Elmers Products Inc., Columbus, OH). The cell contains a sample collection 
chamber in which one of the Ag/AgCl electrodes was placed and the other electrode, which acts 
as a counter electrode, was fixed just adjacent to the cell on the surface of the skin using 
micropore surgical tape (3M Healthcare, St. Paul, MN). The skin was hydrated with 100 µl of 
saline for 5 minutes before each sampling and was replaced with 400 µl of sampling buffer. 
Thirty square electrical pulses each of 1 ms duration at 120 V/cm2 were applied, and the 
sampling fluid remained in the chamber for 15 min after pulsing. The sampling fluid was 
withdrawn, and the amount of glucose present was measured using the glucose assay kit (the 
limits of detection were 0.1-5 mg/dl). 
4.3.4.1. In vivo transcutaneous permeability coefficient 
The calibration used to convert sampling chamber glucose to venous equivalent values is 
nothing but determination of the permeability coefficient in rats having steady normal glucose 
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levels. Constant venous glucose levels were confirmed by triplicate samples. Venous glucose 
levels and corresponding ETS glucose levels of 18 data points in normal rats were used for 
calibration. The normal venous glucose range in Sprague-Dawley rats is ~150-180 mg/dl (122). 
The in vivo permeability coefficient, Pin vivo (cm/min), of rat skin was calculated using the 
formula: 
Pin vivo = 
Glucose flux in 15 min
Venous blood glucose concentration
       (8) 
4.3.4.2. Sampling in diabetes-induced rats 
Nine rats were used, of which three were in the control group and six were in the test 
group. Transcutaneous sampling of glucose by ETS was carried out in the test group only. In the 
control group, transcutaneous sampling was carried out without the application of electrical 
pulses. All nine rats were injected with alloxan (200 mg/kg in saline) intraperitoneally. Generally 
the duration required to induce irreversible diabetes with alloxan is ~24 h (123). Blood and 
transcutaneous samples were obtained in all rats before injecting alloxan and also after 24 and 36 
h after the injection of alloxan. The venous blood glucose was measured using a glucose meter 
(True Track Smart System). From the ETS glucose levels, venous blood glucose concentrations 
are predicted using the formula: 
Venous blood glucose concentration= Glucose flux in 15 min
Pin vivo
      (9)
 
 
4.3.5. Data Analysis 
The clinical utility of the method was determined based on the plot of data on a Clarke 
error grid and determining the percentage of points located in the clinically acceptable A and B 
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zones. Mean absolute relative error was also calculated to estimate the clinical accuracy using 
the formula 
% Mean absolute relative error= Venous glucose-Venous glucose predicted from ETSVenous glucose X 100      (10) 
4.4. RESULTS AND DISCUSSION 
Blood glucose is in homoeostasis with the peripheral tissue extracellular fluid. Therefore, 
any change in the blood glucose is reflected in glucose levels in the tissue extracellular fluid. The 
transdermal permeability of a polar diffusant such as glucose is limited because of the barrier 
properties of stratum corneum. Therefore, transcutaneous sampling of glucose requires a 
technique that can reversibly permeabilize the stratum corneum and facilitate the rapid diffusion 
of glucose from dermal ECF into the sampling fluid. In vitro diffusion studies were carried out 
across the porcine epidermis to assess the feasibility of ETS for sampling glucose. Sampling 
without the application of electrical pulses (control) was not possible, as the glucose transfer by 
passive diffusion was below detectable levels, whereas a significant amount of glucose diffused 
following electroporation of the porcine epidermis. The electrical resistance of the epidermis 
dropped by an average of 70±6% by the application of electrical pulses, indicating 
permeabilization of the skin. In vitro ETS data are represented in Figure 4-1. Along with other 
factors, the rate of diffusion is governed predominantly by the concentration of glucose in the 
dermal extracellular fluid (presuming that the concentration of glucose in the sampling 
compartment is negligible compared to the total glucose concentration in the reservoir 
compartment). Therefore, the amount of glucose sampled by ETS was proportional to the 
concentration of glucose in the reservoir compartment fluid (R2=0.93). The in vitro permeability 
coefficient (Pin vitro) of porcine epidermis permeabilized by electroporation was 1.9±0.3×10-4 
cm/min. 
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Figure 4-1. Relationship between glucose concentration in the reservoir compartment and 
glucose sampled by ETS across porcine epidermis in vitro. 
 
Preclinical studies were carried out in a diabetes-induced Sprague-Dawley rat model to assess 
the workability of the technique in vivo. The moisture content in the rat skin was measured to 
ensure that there was no edema/inflammation in the region of glucose sampling. The 
measurement also confirms the uniformity of degree of hydration of epidermal layers of skin. 
The Delfin moisture meters measure the skin moisture contents in terms of dielectric constant of 
the skin. The average dielectric constant values from moisture meters SC and D were 9.94±1.65 
and 20.67±3.31, respectively. The in vivo permeability coefficient (Pin vivo) of rat skin for glucose 
was found to be 1.95±0.15×10-5 cm/min. Again, a good linear correlation between the venous 
glucose levels and the amount of glucose sampled by ETS was observed (R2=0.87).  
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Generally, Clarke error grid analysis was performed to assess the clinical utility of glucose 
monitoring devices. The analysis divides the reference and measured glucose into five zones-A, 
B, C, D, and E. Values in zones A and B are considered clinically acceptable, whereas values in 
zones C, D, and E lead to significant errors. At this stage we do not know if one can translate 
results from rat model experiments to human application. However, assessing preclinical data 
from a clinical perspective would provide some insight into the clinical applicability of the 
technique. The venous blood glucose determined by blood sampling (x axis) (reference values) 
and that predicted by the ETS techniques (y axis) are shown in Figure 4-2. All data points were 
within Clarke error grid A and B zones. A mean absolute relative error of 12.8% was found for 
all measurements (n=18) from in vivo data. 
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Figure 4-2. Clarke error grid analysis of venous blood glucose (reference) and venous blood 
glucose predicted by ETS in Sprague-Dawley rats. 
 
4.5. CONCLUSIONS 
Results support our hypothesis that the concentration of glucose sampled by ETS would 
be proportional to the concentration of glucose in the dermal extracellular fluid. ETS could be 
developed as a noninvasive method of monitoring blood glucose in people with diabetes.  
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CHAPTER-5 
“CHILDRIVE”: A TECHNIQUE OF COMBINING REGIONAL CUTANEOUS 
HYPOTHERMIA WITH IONTOPHORESIS FOR THE DELIVERY OF DRUGS TO 
SYNOVIAL FLUID 
 
5.1. ABSTRACT 
Bioavailability of drugs in the synovial fluid when administered via transdermal route is 
highly limited due to the dermal clearance. The purpose of this project was to assess the 
efficiency of ChilDrive (CD) technique to improve the drug targeting to the synovial fluid. CD is 
a technique of transdermal delivery of drugs combining regional hypothermia and iontophoresis. 
Diclofenac sodium and prednisolone sodium phosphate were administered by transdermal route 
(Passive, Iontophoresis, Chil-Passive and ChilDrive) at the knee-joint region of hind limb in 
Sprague-Dawley rats for 6 h. Intraarticular microdialysis was carried out to determine the time 
course of drug concentration in the synovial fluid. Drug levels in synovial fluid after intravenous 
and intraarticular administration were also determined. Iontophoretic delivery increased the 
AUC0-t (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery 
(0.86±0.04 and 2.0±0.06 µg.h/ml for diclofenac sodium and prednisolone sodium phosphate 
respectively). CD resulted in an AUC0-t of 5.2±0.69 and 24.6±1.97 µg.h/ml for diclofenac 
sodium and prednisolone sodium phosphate which was ~6-12-fold 
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higher than passive and 2-4-fold higher than iontophoresis. The results support our hypothesis 
that CD improves bioavailability of drugs to the synovial joints. CD could be developed as a 
potential noninvasive technique for treatment of arthritis.  
Keywords: Intraarticular microdialysis; Iontophoresis; Synovial fluid; Transdermal 
5.2. OBJECTIVES AND SIGNIFICANCE 
The objective of the study was: 
I. To assess the effect of iontophoresis combined with regional hypothermia (ChilDrive) for 
enhancing the bioavailability of drugs in the synovial fluid. 
The different types of joints present in the human body are classified into synovial, cartilaginous 
and fibrous joints based on the degree and type of movement. Synovial joints are the most freely 
moveable joints present in the knee, elbow, shoulder, hip, wrist and neck region of the human 
body (124). The presence of lubricating synovial fluid differentiates synovial joints from 
cartilaginous and fibrous joints. Arthritis is the most prevalent disorder affecting synovial joints 
and a major cause of disability among people of all ages. During arthritis, the synovial fluid 
secretion is affected due to the damage caused to the synovial membrane either due to body’s 
own immune cells or due to break down of articular cartilage. This leads to thickening of the 
synovial membrane, eventually resulting in swollen joints and decreased movement between 
bones of the synovial joints. The major types of arthritis include rheumatoid arthritis, 
osteoarthritis, juvenile rheumatoid arthritis and infectious arthritis. Pain and inflammation are 
associated with arthritis (125). The most common treatment modalities for arthritic conditions 
involve oral NSAIDs, including cyclooxygenase (COX) 2 inhibitors and intraarticular injection 
of steroids. NSAIDs act by inhibiting the COX enzymes which are responsible for the 
conversion of arachidonic acid into prostaglandins, which is a major cause of inflammation 
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(126). Corticosteroids suppress the inflammatory parameters, like erythrocyte sedimentation rate 
and C-reactive protein, resulting in decreased disease activity (127). Unfortunately, most of the 
drugs are known to cause severe gastric irritation and other gastrointestinal disturbances 
following oral administration. In addition, the systemic side effects are unavoidable due to 
distribution of drugs (128, 129). Moreover, the amount of drug reaching the synovial joint would 
be only a small fraction of the total administered dose. Although intraarticular injections provide 
maximum bioavailability in the synovial cavity, they are invasive in nature and therefore do not 
allow frequent administration (130). Harvey and Hunter suggested that the number of injections 
in a single joint should not be more than four in a single year (131). 
The synovial fluid present in joints is an ultrafiltrate of plasma which is continuously absorbed 
and replenished by synovial lining of joint cavity, with a rapid turnover time of ~2 h (132, 133). 
This is one of the main constraints in the treatment of arthritis as it results in rapid clearance of 
drug from the synovial cavity. This necessitates either frequent administration or continuous 
infusion of drugs into the synovial fluid to maintain effective level of drugs through the course of 
treatment. In an infusion-type drug delivery system, a steady state drug level could be maintained 
over prolonged durations. However, intraarticular infusion is practically not feasible unless the 
patient is hospitalized and bedridden. 
Transdermal delivery of drugs is noninvasive and is associated with advantages such as steady 
state input of drugs, prolonged therapeutic activity, and minimized gastrointestinal and systemic 
side effects. However, passive delivery of drugs through skin is not capable of achieving 
required drug levels in the subdermal musculoskeletal tissues mainly due to the fact that the 
majority of the drug that penetrates into skin will be cleared by the dermal circulation (134, 135). 
One of the approaches to enhance deeper penetration of drugs is likely to increase the rate of 
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drug delivery higher than the rate of dermal clearance (dQ/dt>Rcl) (Figure 5-1). The rate of drug 
delivery is known to increase when iontophoresis is applied across the skin due to the repulsive 
driving force on the drug ions. However, the rate of drug delivery by iontophoresis across skin is 
limited by the maximum current density that can be applied. The maximum current that is 
tolerable and safe is in the range of 0.4-0.5 mA/cm2 (136, 137). 
 
 
Figure 5-1. Skin and subdermal tissues. dQ/dt represents rate of drug permeation across skin and 
Rcl represents rate of dermal clearance of drug. The amount of drug reaching the subdermal 
tissues could be increased by rendering Rcl<dQ/dt. 
 
The second approach would be to reduce the rate of dermal clearance in order to accumulate 
drug in the dermal tissue. Some research groups have attempted to enhance the delivery of drugs 
to subdermal tissues by reducing the rate of dermal clearance with the help of vasoconstrictors 
(138). Vasoconstrictors constrict the blood vessels and there-by reduce the blood perfusion rate 
(thus the drug clearance) in the tissue. Higaki et al. have shown that there was ~3.3-9.6-fold 
enhancement in the amount of antipyrine, salicylic acid, and diclofenac reaching muscle 
followed by reducing blood flow upon topical administration of vasoconstrictor phenylephrine 
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(139). But the use of vasoconstrictors over long durations is likely to cause severe undesirable 
systemic and cardiovascular effects. Therefore, use of a biophysical technique that reduces the 
regional blood perfusion would be safer than the vasoactive drugs. 
Vuksanovic and coworkers studied the effect of temperature on the regional blood flow in skin 
and have shown that when the skin temperature is >31 °C, the blood flow in the skin remains 
constant. However, a rapid decrease in blood flow can be seen when skin temperature drops  <31 
°C due to vasoconstriction (140). Unlike the vasoactive drugs, temperature induced 
vasoconstriction is a regional effect and hence regarded as relatively safe. 
Diclofenac sodium and prednisolone sodium phosphate were selected as model drugs to assess 
our hypothesis that regional hypothermia during iontophoretic transdermal delivery at the joints 
leads to increased bioavailability of drugs in the synovial fluid. 
5.3. MATERIALS AND METHODS 
5.3.1. Chemicals 
Diclofenac Sodium, Prednisolone Sodium Phosphate were procured from Sigma-Aldrich 
Inc (St. Louis, MO), Phosphate buffered saline (PBS, pH 7.4) premixed powder was obtained 
from EMD Chemicals (Gibbstown, NJ) and all other chemicals were obtained from Fischer 
scientific (Fairway, NJ). 
5.3.2. Animals  
All the experimental studies were performed on 24 male Sprague-Dawley rats (200-250g) 
under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia administered intraperitoneally. 
The rats were procured from Harlan (Indianapolis, IN) and maintained on a 12-12 h light/dark 
cycle in an animal facility with unlimited access to food and water. The animal studies were 
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approved by the Institutional Animal Care and Use Committee (IACUC) at the University of 
Mississippi (Protocol#09-006). 
5.3.3. Intraarticular microdialysis 
Intraarticular microdialysis was carried out to determine the amount of drug present in 
the synovial fluid. After anaesthetizing the rats, the hind limb was held in a fixed position and an 
introducer needle with split tubing was passed through the knee joint capsule, the needle was 
removed and a CMA 20 microdialysis probe of 4 mm length and 20 kDa molecular weight cut 
off (CMA, North Chlemsford, MA) was inserted through the split tubing. The split tubing was 
withdrawn leaving the probe implanted in the synovial cavity. The implantation of probe in the 
synovial cavity of rat is shown in Figure 5-2. PBS was perfused for 30 min prior to drug 
administration for equilibration at flow rate of 2 µl/min. The probe recovery was determined in 
vivo by using retrodialysis method. The proper placement of the probe in the synovial cavity was 
confirmed by making an incision at the site of probe implantation after completion of studies. 
 
 
Figure 5-2. Microdialysis probe implanted in the knee-joint for carrying out synovial fluid 
microdialysis in hind limb of rat. 
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5.3.4. Intravenous and intraarticular delivery of drugs 
Diclofenac sodium and prednisolone sodium phosphate were given by intravenous route 
through the tail vein (4 mg/kg) and intraarticular microdialysis was carried out for 6 h to 
determine the time course of drug reaching the synovial fluid. Also, drug solutions were injected 
directly into the synovial cavity (50 µl) in separate set of rats and intraarticular microdialysis was 
carried out for 6 h. 
5.3.5. Transdermal drug delivery 
5.3.5.1. Design of iontophoretic patch 
The iontophoretic patch (Figure 5-3) was fabricated using a woven adhesive backing 
membrane fitted with a snap type Ag/AgCl electrode. One cm2 foam pad was attached onto the 
backing membrane above the electrode. Drug solution (1%) made in PBS was filled in the foam 
pad just before the application of patch. Similar patch was made which was filled with PBS and 
acts as counter electrode.  
The patch containing drug solution was placed on the lateral side of the rat knee and the counter 
electrode was placed on the opposite side for all the transdermal drug delivery studies. 
Intraarticular microdialysis was carried out for 6 h and the dialysate was collected every hour to 
determine the amount of drug reaching the synovial fluid. In all the cases, drug containing patch 
was applied only after the equilibration of microdialysis probe in the synovial joint. 
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Figure 5-3. Design of iontophoretic patch with ‘A’ displaying the dorsal view and ‘B’ displaying 
the ventral view. 
 
5.3.5.2 Passive drug delivery  
Passive drug delivery studies were carried out for both the drugs by using the patches 
fabricated with electrodes to maintain similar experimental conditions compared to 
iontophoresis. In passive drug delivery, no current was applied.  
5.3.5.3 Iontophoretic drug delivery 
Iontophoresis was carried out using an IOMED Phoresor (Iomed Inc, Salt Lake city, UT) 
by connecting the lead clips from the iontophoresis unit to the snap on the drug electrode and 
counter electrode. Electrical current of 0.5 mA/cm2 was applied continuously for 6 h.  
5.3.5.4. Chil-Passive drug delivery 
Passive drug delivery carried out under regional hypothermia was termed as “chil-
passive” drug delivery. Regional hypothermia was induced by placing the hind limb of the rats 
on a water pad circulated continuously with water at reduced temperature (15-20 ○C) for the 
entire period of study. 
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5.3.5.5. ChilDrive (CD) drug delivery 
Iontophoresis carried out under regional hypothermia was termed as “ChilDrive” (CD). 
Regional hypothermia was induced according to method mentioned earlier. With exception of 
regional hypothermia, all other experimental conditions were similar to iontophoretic drug 
delivery. 
5.3.6. Analytical methods 
The amount of diclofenac sodium and prednisolone sodium phosphate present in 
microdialysis samples was analyzed by high performance liquid chromatography. The HPLC 
system (Waters, MA) consisted of a chromatographic pump (Waters 1525), an autosampler 
(Waters 717 plus), a UV detector (Waters 2487) and a Symmetry® C18 column (4.6 x 150 mm). 
Analysis of diclofenac sodium samples was carried out at a wavelength of 278 nm and the 
mobile phase consisted of a mixture of acetonitrile and 0.01 M  potassium dihydrogen phosphate 
(pH 6.3), (35:65 v/v) with flow rate of 1 ml/min (141). The linearity range was between 10-1000 
ng/ml (R2=0.99). 
Analysis of prednisolone sodium phosphate samples was carried out at a wavelength of 242 nm 
and the mobile phase was prepared by mixing 250 ml of isopropanol with 2 ml H3PO4 and 
diluting with water to 900 ml. The pH of the solvent was adjusted to 3.0 with 1.0 M NaOH and 
then diluted to 1000 ml with water and the flow rate was set to 1 ml/min (142). The linearity 
range was between 10-1000 ng/ml (R2=0.99). 
5.3.7. Statistical analysis 
The statistical analysis of AUC0-t data after transdermal, intravenous and intraarticular 
administration were determined by performing Unpaired t-test (GraphPad, InStat 3.0) to 
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determine the level of significance between two groups. P<0.05 was considered as the level of 
significance. 
5.4. RESULTS AND DISCUSSION 
Microdialysis technique was employed as a tool to investigate the time course of drug 
concentration in the synovial fluid (79, 143). The in vivo probe recovery was performed using 
retrodialysis method and was found to be 19.28±4.99% for diclofenac sodium and 23.01±5.48% 
for prednisolone sodium phosphate. 
5.4.1. Intravenous and intraarticular delivery of drugs 
Drugs were administered intravenously to determine the fraction of the total dose 
reaching the synovial fluid. The time course of drug in the synovial fluid upon intravenous 
administration is shown in Figure 5-4 and 5-5. 
The AUC0-t in the synovial fluid after intravenous administration was found to be 0.609±0.02 
µg.h/ml for diclofenac and 1.445±0.17 µg.h/ml for prednisolone. The total AUC0-t in the 
synovial fluid by systemic administration was comparable with that of passive topical delivery of 
drugs (Table 5-1 and 5-2) and was significantly less than all the other modes of drug 
administration. From these results it appears that the systemic delivery of drug for treating 
synovial disorders may not end in remarkable results unless the dose and frequency are high 
enough to maintain effective drug levels over long duration.  
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Figure 5-4. Time course of diclofenac sodium in synovial fluid upon intraarticular (●) and 
intravenous (■) administration. 
 
The Cmax and Tmax in synovial fluid for diclofenac following intravenous administration were 
0.174 µg/ml and 4 h. Similarly for prednisolone sodium phosphate they were found to be 0.339 
µg/ml and 2 h. Obviously, delivery of drugs directly into the synovial cavity resulted in 
significantly higher bioavailability than all the other modes of drug administration (Table 5-1 
and 5-2). The concentration-time profile followed a mono-exponential disposition curve (Figure 
5-4 and 5-5). 
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Figure 5-5. Time course of prednisolone sodium phosphate in synovial fluid upon intraarticular 
(●) and intravenous (■) administration. 
Table 5-1. AUC0-t and Cmax of diclofenac sodium in synovial fluid  following transdermal 
(Passive, Chil-Passive, Iontophoresis, ChilDrive), intravenous and intraarticular administration. 
   
 AUC0-t (µg.h/ml) Cmax (µg/ml) 
Passive 0.864 ± 0.042 0.188 ± 0.022 
Chil-Passive 1.336 ± 0.105 0.287 ± 0.024 
Iontophoresis 2.683 ± 0.152 0.644 ± 0.036 
ChilDrive 5.208 ± 0.693 1.259 ± 0.098 
Intravenous 0.609 ± 0.028 0.174 ± 0.009 
Intraarticular 77.829 ± 5.422 25.974 ± 1.340 
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Table 5-2. AUC0-t and Cmax of prednisolone sodium phosphate in synovial fluid following 
transdermal (Passive, Chil-Passive, Iontophoresis, ChilDrive), intravenous and intraarticular 
administration. 
   
 AUC0-t (µg.h/ml) Cmax (µg/ml) 
Passive 2.003 ± 0.067 0.468 ± 0.106 
Chil-Passive 3.958 ± 0.303 0.863 ± 0.055 
Iontophoresis 6.364 ± 0.486 1.724 ± 0.423 
ChilDrive 24.605 ± 1.975 7.360 ± 1.032 
Intravenous 1.445 ± 0.174 0.339 ± 0.032 
Intraarticular 479.946 ± 45.040 141.890 ± 20.179 
 
The AUC0-t in synovial fluid after intraarticular administration was 77.82±5.42 and 
479.94±45.04 µg.h/ml for diclofenac sodium and prednisolone sodium phosphate respectively. 
However, one should note that the drugs administered into the synovial cavity were eliminated 
rapidly as reflected by the elimination half-lives of drugs in the synovial fluid (t1/2 was 1.55±0.02 
h for diclofenac and 1.19±0.01 h for prednisolone respectively). The rapid elimination of drug 
could be attributed to the rapid turnover of synovial fluid and/or to the metabolism of drug in the 
synovial fluid. Relatively longer half-life of diclofenac in the synovial fluid is likely due to 
slightly higher protein binding (>98%) compared to prednisolone (65-91%) (144, 145). 
5.4.2. Passive drug delivery  
Vuksanovic et al. have clearly demonstrated using the laser doppler studies that the blood 
perfusion rate in the skin tissue is decreased under hypothermic conditions (140). The decreased 
blood flow is likely to result in decreased rate of dermal clearance of drugs. Passive drug 
delivery studies were carried out at normal body temperature and at regional hypothermia 
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condition (Chil-Passive) for both the drugs. The drug concentration-time profile in the synovial 
fluid was used to calculate the AUC0-t. The total AUC0-t in synovial fluid after passive 
transdermal administration of drugs was almost doubled due to induction of regional 
hypothermia (Table 5-1 and 5-2). 
5.4.3. Iontophoretic drug delivery 
Application of iontophoresis (0.5 mA/cm2) resulted in enhanced bioavailability of drugs 
into the synovial cavity (Figure 5-6 and 5-7). Iontophoresis mediated delivery of drugs resulted 
in 3-fold (P<0.01) higher AUC0-t in synovial fluid compared to passive drug delivery (Table 5-1 
and 5-2). These results are in agreement with previous reports in which other authors showed 
that iontophoresis aids in better treatment of joint disorders. Aiyejusunle et al. have reported that 
cathodal iontophoresis (0.1-0.3 mA/cm2) of sodium salicylate resulted in reduced pain and 
functional disability. Bender et al. have shown that the concentration of etofenamate in the 
synovial fluid following iontophoresis was twice that of etofenamate levels in serum and hence 
topical iontophoresis of etofenamate was suitable for alleviation of arthritis in superficially 
located joints (146, 147). 
In case of CD, iontophoresis was carried out by placing hind limb portion of rat on a water pad 
through which water at 20 ºC was circulated, so that temperature of skin was maintained in the 
range of ~20-25 ºC throughout the study. Reducing skin temperature has been widely used in 
treatment techniques like cryotherapy where-in temperatures in the range of 7-20 ○C have been 
used. As hypothermia is induced regionally in the present studies, it is less likely to lead to any 
physiological changes in the whole body. Chesterton et al. reported that physiological changes 
like local analgesia, reduced nerve conduction velocity, and reduced metabolic enzyme activity 
are seen only at temperatures below 14 ○C (148). 
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Figure 5-6. Time course of diclofenac sodium in the synovial fluid following different modes of 
transdermal administration (♦-Passive, ■-Chil-Passive, ▲-Iontophoresis and ●-ChilDrive). 
 
The AUC0-t of drug in the synovial fluid due to CD was ~2-4-fold (P<0.01) higher than 
iontophoresis in case of both the drugs. This is exactly the fold of enhancement observed 
between passive transdermal and chil-passive as well. Compared to passive drug delivery, the 
AUC0-t in the synovial fluid of drugs when administered by CD was ~6-12-fold higher (P<0.01). 
Interestingly, all the synovial concentration-time profiles following transdermal drug 
administration showed a typical initial increase followed by decrease in drug concentration 
regardless of the mode of drug delivery. It is likely that the change in the synovial fluid turnover 
rate due to insertion of the probe might have caused this kind of concentration-time profile.  
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Figure 5-7. Time course of prednisolone sodium phosphate in the synovial fluid following 
different modes of transdermal administration (♦-Passive, ■-Chil-Passive, ▲-Iontophoresis and 
●-ChilDrive). 
5.5. CONCLUSION 
Regional hypothermia is one the most promising approaches to reduce the rate of clearance of 
drug from the skin. ChilDrive can be developed as a potential way of treating musculoskeletal 
disorders. The technology is likely to be more patient compliant than oral or parenteral delivery 
of drugs. 
“With kind permission from Springer Science+Business Media: Pharmaceutical Research, 
“ChilDrive”: A technique of combining regional cutaneous hypothermia with iontophoresis for 
delivery of drugs to synovial fluid, 26, 2009, 2535-2540, Srinivasa M. Sammeta and S. 
Narasimha Murthy.”  
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CHAPTER-6 
MAGNETOPHORESIS FOR ENHANCING TRANSDERMAL DRUG DELIVERY: 
MECHANISTIC STUDIES AND PATCH DESIGN 
 
6.1. ABSTRACT 
Magnetophoresis is a method of enhancement of drug permeation across biological 
barriers by the application of magnetic field. The present study investigated the mechanistic 
aspects of magnetophoretic transdermal drug delivery and also assessed the feasibility of 
designing a magnetophoretic transdermal patch system for the delivery of lidocaine. In vitro drug 
permeation studies were carried out across the porcine epidermis at different magnetic field 
strengths. The magnetophoretic drug permeation “flux enhancement factor” was found to 
increase with the applied magnetic field strength. The mechanistic studies revealed that the 
magnetic field applied in this study did not modulate permeability of the stratum corneum 
barrier. The predominant mechanism responsible for magnetically mediated drug permeation 
enhancement was found to be “magnetokinesis”. The octanol/water partition coefficient of drugs 
was also found to increase when exposed to the magnetic field. A reservoir type transdermal 
patch system with a magnetic backing was designed for in vivo studies. The dermal 
bioavailability (AUC0-6h) from the magnetophoretic patch system in vivo in rats was significantly 
higher than the similarly designed non-magnetophoretic control patch. 
Keywords: Magnetophoresis; Transdermal; Lidocaine; Partition coefficient; Enhancer 
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6.2. OBJECTIVES AND SIGNIFICANCE 
The objectives of the study are: 
I. To investigate the technique of magnetophoresis for enhancing transdermal drug 
permeation. 
II. To resolve the mechanisms leading to enhanced transdermal drug permeation by 
magnetophoresis. 
III. To assess the feasibility of designing a simple magnetophoretic transdermal patch 
system. 
Transdermal permeation of polar and hydrophilic drugs is limited by the barrier property of 
stratum corneum. Therefore, several chemical and physical permeation enhancement techniques 
have been explored to improve the transdermal delivery of poorly permeable drugs (29, 149-
151). In this direction, Murthy et al. investigated the plausibility of using magnetic field to 
enhance the transdermal permeation of drugs. The authors reported for the first time that the 
static magnetic field could facilitate the transdermal permeation of drugs such as benzoic acid, 
salbutamol sulfate and terbutaline sulfate (152, 153). The authors speculated that the enhanced 
transdermal drug permeation by the applied magnetic field could be a combination of multiple 
mechanisms such as magnetokinesis and alteration of barrier property of skin. A recent study by 
Krishnan et al. utilized an electromagnetic field to enhance the drug permeation across the skin. 
Krishnan et al. reported that the potential mechanism for enhanced transdermal drug permeation 
by the electromagnetic field of 5 mT was due to modulation of the permeability of stratum 
corneum (154). There are a number of reports regarding the use of magnetite incorporated 
particulate systems in drug delivery and imaging. An externally applied magnetic field has been 
shown to direct the systemically administered magnetoliposomes or nanoparticles to the target 
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tissue (155, 156). The mechanism associated with this approach is attraction of the ferromagnetic 
substance, magnetite, towards the magnetic field. The present project involved delivery of a drug 
across the skin by application of magnetic field, where drug molecules which are diamagnetic in 
nature are repelled away from the magnetic field. The base and salt form of a local anesthetic, 
lidocaine which is a diamagnetic molecule was selected as the candidate for the present study. 
6.3. MATERIALS AND METHODS 
6.3.1. Materials 
Lidocaine Hydrochloride (LH) was purchased from Spectrum Chemicals (New 
Brunswick, NJ), lidocaine base (LB), D-mannitol and sodium chloride were procured from 
Sigma-Aldrich Inc. (St. Louis, MO). [3H] Water and D-[1-14C] Mannitol were procured from 
American Radiolabeled Chemicals, Inc. (St. Louis, MO) and all other chemicals were obtained 
from Fischer Scientific (Fairway, NJ). Neodymium magnets were purchased from United 
Nuclear Scientific (Laingsburg, MI) and K&J Magnetics, Inc. (Jamison, PA). 
6.3.2. Porcine epidermis 
Porcine belly skin was obtained from a local abattoir. Pieces of skin wrapped in 
aluminum foil were heated to 60 ºC for 2 min and the epidermis was gently peeled off the skin. 
The fresh epidermis was placed on glass microscopic slides and kept dry at 4 ºC and was used 
within three days. Prior to use, the epidermis was hydrated with normal saline for an hour.   
6.3.3. General in vitro experimental setup  
A vertical Franz-type diffusion apparatus (PermeGear, Inc. Hellertown, PA) was used for 
all resistance measurements and drug permeation studies across the porcine epidermis. A piece 
of porcine epidermis was placed between the two compartments of the diffusion apparatus, one 
serving as the donor and other as the receiver compartment. The active diffusion area of the 
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epidermis was 0.2 cm2. The receiver compartment (5 ml) and donor compartment (0.2 ml) were 
filled with isotonic saline solution. Ag/AgCl electrode wires of 0.5 mm diameter (Alfa Aesar, 
Ward Hill, MA) made in the form of concentric rings were placed 2 mm away from the porcine 
epidermis in both the donor and the receiver compartments. Before carrying out permeation 
studies, the electrodes were connected to the electrical set up for resistance measurement. The 
electrical resistance of the epidermis was measured and only pieces of epidermis, which had 
resistances greater than 20 kΩ.cm2 were used for the experiments. During the in vitro drug 
permeation studies the temperature of receiver compartment was maintained at 37±1 ○C by water 
circulation.  
6.3.4. Passive drug permeation studies 
After the electrical resistance measurement, the isotonic saline in the donor compartment 
was replaced with 0.2 ml of LH solution (10 mg/ml) or LB solution (1.66 mg/ml) prepared in 
isotonic saline and the permeation studies were carried out for 8 h. During the course of 
permeation studies, at each sampling time point (2, 3, 4, 5, 6, 7 and 8 h) 0.2 ml of the receiver 
compartment solution was sampled out, and was subsequently replaced with fresh isotonic saline 
solution. The amount of drug in the samples was analyzed by HPLC.  
6.3.5. Magnetophoretic drug permeation studies 
The experimental set up was similar to passive drug permeation studies, and  the 
magnetic field was applied by placing two neodymium magnets (1.2 cm length x 0.6 cm width x 
0.6 cm thickness) on either side of the donor compartment and at a distance of 2 mm above the 
porcine epidermis (Figure 6-1). Permeation studies were carried out for 8 h at different magnetic 
field strengths of 30, 150 and 300 mT. The amount of drug permeated across porcine epidermis 
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into the receiver compartment solution was determined by analyzing the samples withdrawn at 
different time points as discussed in section 6.3.4.  
 
 
Figure 6-1. Experimental set up for permeation studies. Porcine epidermis ‘A’ was sandwiched 
between the donor compartment ‘B’ filled with drug solution and receiver compartment ‘C’ 
filled with isotonic saline. Two neodymium magnets ‘D’ were placed on either side of the donor 
compartment. The donor and receiver compartments were fitted with Ag/AgCl electrode wires 
for measurement of electrical resistance. 
6.3.6. Drug permeation across the dialysis membrane 
The drug permeation studies were carried out across Spectra/Por® dialysis membrane 
(1000 Da molecular weight cut-off) in the absence and presence of magnetic field (300 mT) 
following exactly the same procedure described in the passive and magnetophoretic drug 
permeation studies (Section 6.3.4 and 6.3.5). 
6.3.7. Drug permeation across the pretreated epidermis (epidermis exposed to magnetic 
field)  
The porcine epidermis was pretreated (for 24 h) by exposure to the magnetic field by 
using a similar set up as shown in Figure 6-1, without placing any medium in the donor 
compartment. After the pretreatment, the donor chamber was filled with drug solution and the 
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passive drug permeation studies were carried out across the pretreated epidermis similar to that 
discussed in section 6.3.4. 
6.3.8. [3H] Water and D-[1-14C] Mannitol transport studies  
The experimental set up was similar to that used for the passive and magnetophoretic 
drug permeation studies (Section 6.3.4 and 6.3.5). The donor compartment was filled with 0.2 ml 
of [3H] water (20 µCi/ml) in isotonic saline for water transport studies. Mannitol (1 mg/ml) and 
[1-14C] mannitol (5 µCi/ml) in isotonic saline was placed in the donor compartment for mannitol 
transport studies. The receiver compartment was filled with isotonic saline in both the studies. In 
the case of magnetophoretic permeation studies, a magnetic field of 300 mT was applied. After 
the passive and magnetophoretic permeation studies, tritiated water and mannitol transport across 
porcine epidermis was measured by withdrawing samples at regular intervals for a period of 8 h. 
The amount of [3H] water and [14C] mannitol was determined by scintillation counting 
(Scientisafe Econo 2 cocktail, Fischer Scientific, Fairway, NJ; liquid scintillation analyzer, Tri-
Carb 1600 TR, Packard Bioscience, Meriden, CT).  
6.3.9. Transepidermal Water Loss (TEWL) studies 
The TEWL was measured using a Vapometer (Delfin Technologies, Kuopio, Finland). 
Porcine epidermis was mounted between the receiver and donor compartments of the diffusion 
cell (Figure 6-1). Isotonic saline solution was placed only in the receiver compartment and the 
donor compartment was kept empty. The whole set up was placed in a temperature (37 °C) and 
humidity (RH 55%) controlled chamber and the TEWL was measured by fixing the Vapometer 
directly on the donor compartment. TEWL was measured prior to the start of the experiment. 
The test set was exposed to magnetic field (300 mT). The TEWL was measured at different time 
points up to 8 h. 
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6.3.10. Fourier Transform Infrared (FT-IR) spectroscopic studies 
The porcine epidermis was subjected to FT-IR spectroscopic studies in absence and 
presence of magnetic field. Infrared spectra were obtained in the transmission mode using a 
Nicolet 6700 FT-IR spectrometer in the frequency range 4000-1000 cm-1. Sixty four scans were 
collected at 4 cm-1 resolution. The same piece of porcine epidermis was used for recording the 
spectra in absence and presence of magnets. Two magnets were placed on the surface of porcine 
epidermis at a distance of 6 mm with unlike poles facing each other (magnetic field of 300 mT) 
for recording the spectra. The magnets used, distance between magnets and polarity were same 
as those used for in vitro permeation studies. 
6.3.11. Effect of magnetic field on octanol-water and stratum corneum (SC)-aqueous 
vehicle partitioning of drug  
To determine the octanol-water partition coefficient, deionized water equilibrated with an 
equal volume of octanol was used to prepare the drug solution. 0.2 ml of drug solution 
(concentrations of 50, 100, 250 and 500 µg/ml) was placed in contact with 0.2 ml of octanol in a 
glass vial. The two phases were mixed thoroughly by vigorous shaking for 6 h and allowed to 
equilibrate for next 18 h. After equilibration, 20 µl of aqueous and octanol phases were 
withdrawn for measurement and calculation of “initial partition coefficient”. The vials from the 
test group were placed in presence of magnetic field (300 mT) and the control set were not. Only 
the aqueous phase was placed in presence of magnetic field. After 24 h, the “final partition 
coefficient” of the drug in the control and test set of vials was determined. The average 
difference in the partition coefficient (final partition coefficient value-initial partition coefficient 
value) was compared between control and the test sets.  
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To determine SC-vehicle partition coefficient, preweighed samples of SC (isolated by trypsin 
digestion method as shown by Essa et al.) were placed in 0.2 ml of drug solution in isotonic 
saline (100 µg/ml) in a glass vial for 48 h (157). A magnetic field of 300 mT was applied on the 
bulk of the vehicle in the vial, only to the test group. At the end of 48 h, the amount of drug 
present in the vehicle and SC were measured to estimate the partition coefficient of drug.    
6.3.12. Fabrication of magnetophoretic transdermal patches  
Magnetophoretic transdermal patches were designed by affixing a series of neodymium 
magnets (10 mm length x 1.5 mm width x 1.5 mm thickness) on a nonmagnetic backing 
membrane which is placed over an adhesive 3M™ foam tape (3M Drug Delivery Systems, St. 
Paul, MN). About 200 mg of LH and LB gel (2% w/w) prepared in HPMC base (4% w/v) was 
spread over the magnets (1.5 cm2) as a thin layer, which acts as drug reservoir. The magnetic 
field strength at the skin surface of the magnetophoretic patch system was 450 mT. In the case of 
passive transdermal patches, the neodymium magnets were replaced with similar nonmagnetic 
metal pieces. 
LH gel was prepared using HPMC in deionized water; whereas, LB gel was prepared using 
HPMC in hydroalcoholic solution (water:alcohol, 70:30) due to the limited solubility of LB in 
aqueous medium. 
6.3.13. In vivo dermal bioavailability studies of magnetophoretic patch system 
The animal studies were approved by the Institutional Animal Care and Use committee 
(IACUC) at the University of Mississippi (Protocol#09-031). The in vivo studies were performed 
on 12 male Sprague-Dawley rats (200-250 g) under ketamine (80 mg/kg) and xylazine (10 
mg/kg) anesthesia administered intraperitoneally. The rats were procured from Harlan 
(Indianapolis, IN). 
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Cutaneous microdialysis was carried out in rats by inserting a 20G needle intradermally through 
a distance of 2 cm and a linear microdialysis probe of 5 mm membrane length and 30 kDa cut-
off molecular weight (BASi, West Lafayette, IN) was inserted through this needle and the needle 
was withdrawn leaving the probe implanted in the dermal tissue. The inlet tube was connected to 
an injection pump (BASi, West Lafayette) and isotonic saline solution was perfused at a flow 
rate of 2 µl/min. After equilibration of the probe for 30 min, a transdermal patch system was 
placed above the region where microdialysis probe was inserted and studies were carried out for 
a period of 6 h. For both the salt (LH) and base (LB) forms of the drug, animal studies were 
performed using passive and magnetophoretic patch systems respectively. The probe recovery 
was determined in vivo by retrodialysis method. 
6.3.14. Analytical method 
The amount of lidocaine hydrochloride and lidocaine were analyzed by high performance 
liquid chromatography. The HPLC system (Waters, MA) consisted of a chromatographic pump 
(Waters 1525), autosampler (Waters 717 plus) and an UV absorbance detector (Waters 2487). 
Symmetry® C18 column (4.6 x 150 mm) was used and the mobile phase consisted of a mixture 
(14/86 v/v) of acetonitrile and potassium dihydrogen phosphate 0.05 M (pH adjusted to 4.0) 1.3 
ml/min at 216 nm (158). 
6.3.15. Statistical analysis 
Statistical analysis was carried out using GraphPad InStat 3 software. Unpaired t-test was 
performed and P<0.05 was considered as the level of significance. 
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6.4. RESULTS AND DISCUSSION 
Porcine epidermis has been accepted as one of the most appropriate models for 
transdermal drug delivery studies due to its similarities in structure and lipid composition of 
stratum corneum with the human (159-161). Therefore, porcine epidermis was employed in all 
the in vitro experiments in the present study. The magnetic field of different strengths (30-
300 mT) was generated by varying the distance between the poles of bar magnets or by using 
magnets of different strengths. The magnetic field strengths were measured at the surface of the 
epidermis using a hand-held Gauss/Tesla meter (F.W. Bell, Model # 4048). 
6.4.1. Magnetophoresis of LH across the porcine epidermis 
The data from Figure 6-2 and Table 6-1 clearly demonstrate the ability of magnetic field 
to enhance the permeation of LH across the porcine epidermis. The permeation flux 
enhancement factor (EF) (Permeation flux in presence of magnetic field / flux in absence of 
magnetic field) was found to increase linearly with increasing applied magnetic field strength as 
shown in the insert graph in Figure 6-2. The relationship between the permeation flux 
enhancement factor for LH and magnetic field strength could be presented as EF = 0.027S+1, 
(R2=0.92) where ‘EF’ is the flux enhancement factor and ‘S’ is the strength of magnetic field at 
the surface of the epidermis.  
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Figure 6-2. Cumulative permation of  LH across porcine epidermis in case of passive (♦), 
magnetic field strength of 30 mT (■), 150 mT (▲) and 300 mT (●). Insert graph shows plot of 
magnetic field strength vs. flux enhancement factor. 
 
Table 6-1. Permeation flux and  flux enhancement factor of LH and LB across porcine 
epidermis. 
 
Magnetic 
field (mT) 
LH LB 
Permeation flux 
(µg/cm2/h) 
Flux 
enhancement 
factor (EF) 
Permeation 
flux (µg/cm2/h) 
Flux 
enhancement 
factor (EF) 
0 0.18 ± 0.06 1.0 0.57 ± 0.12 1.0 
30 0.53 ± 0.09 2.9 0.75 ± 0.18 1.3 
150 1.01 ± 0.17 5.6 1.14 ± 0.29 2.0 
300 1.61 ± 0.12 8.9 2.23 ± 0.22 3.9 
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The concept of utilizing magnetic field for enhancement of transdermal drug delivery emanated 
from the hypothesis that diamagnetic substances, which are generally repelled away from the 
external magnetic field would be driven across the biological barrier along the direction of the 
magnetic field gradient. However, the diamagnetic susceptibility is considered to be a very weak 
property and the driving force generated under mT range magnetic field is regarded as rather 
mild. Despite this, a significant transdermal permeation enhancement of drug was observed in 
the presence of magnetic field suggesting that the magnetophoresis phenomenon could involve 
multiple mechanisms.  
Generally, transdermal physical permeation enhancement techniques are known to cause 
enhanced drug permeation across the biological barriers by mechanisms such as kinesis of drug 
molecules and/or by alteration of the biological barrier. Iontophoresis is one of the techniques 
which is known to enhance the transdermal drug permeation predominantly by driving the drug 
ions due to electrorepulsion. On the other hand, techniques such as electroporation, sonophoresis 
and thermoporation enhance the transdermal delivery of drugs by disruption of the stratum 
corneum barrier. To resolve the role of different mechanisms in case of magnetophoresis, 
systematic mechanistic studies were carried out as discussed further in this study. 
6.4.2. Permeation across the pretreated epidermis (epidermis exposed to magnetic field)  
To assess the plausible effect of an applied magnetic field on the barrier property, the 
epidermis was pretreated by exposure to magnetic field (30, 150 and 300 mT) for 24 h. Passive 
permeation studies (in absence of magnetic field) were carried out across the pretreated 
epidermis. Permeation experiments across the untreated epidermis served as control. The 
permeation flux across the epidermis did not differ significantly between pretreated and 
untreated epidermis suggesting that prior exposure of the epidermis to magnetic field did not 
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bring about any long lasting change in the epidermal permeability (Table 6-2). However, this 
experiment did not rule out the possibility of any potential real time microstructural changes in 
the epidermis during the magnetophoretic drug permeation studies. 
Table 6-2. Permeation flux of LH and LB across pretreated porcine epidermis (Epidermis 
exposed to magnetic field for 24 h). The epidermis was exposed to different magnetic field 
strengths and the drug permeation studies were carried out across the pretreated epidermis. 
 
Pretreatment 
Magnetic field (mT) 
Permeation flux after pretreatment (µg/cm2/h) 
LH  LB 
0 0.17 ± 0.05 0.59 ± 0.09 
30 0.18 ± 0.03 0.56 ± 0.13 
150 0.16 ± 0.06 0.60 ± 0.19 
300 0.17 ± 0.03 0.57 ± 0.16 
 
TEWL and electrical resistance have been considered as two promising parameters used to 
assess the barrier integrity of the stratum corneum (162, 163). However, TEWL is known to be 
relatively less sensitive than electrical resistance as it can only reflect mechanical disruption of 
the barrier. On the other hand, electrical resistance is relatively more sensitive and could change 
significantly even due to any microstructural changes in the stratum corneum. TEWL and 
electrical resistance of the porcine epidermis were measured at different time points while the 
epidermis was being exposed to magnetic field. The initial TEWL and electrical resistance of the 
porcine epidermis was 6.15±0.71 g/m2/h and 38.1±1.2 kΩ.cm2 respectively. The TEWL value 
across the intact epidermis that has been reported by other groups agrees well with that found in 
this case (164, 165). The TEWL and electrical resistance remained constant during study period 
of 8 h. Therefore, it is most likely that, at the applied magnetic field strengths in these 
experiments, no significant real time transient structural alterations occurred in the epidermis.  
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To further confirm the non-interaction of the magnetic field with the stratum corneum lipids, the 
epidermis were subjected to FT-IR studies. The FT-IR spectra of the stratum corneum side were 
recorded before and after exposure to the magnetic field. A custom designed skin holder was 
used to hold the magnets in place even while the spectra were recorded. There was no significant 
shift in the peaks in the lipid region (2920 and 2850 cm-1) or in the amide regions (1650 and 
1550 cm-1) as clearly seen in the representative spectra shown in Figure 6-3, even after exposure 
to magnetic field for over 80 h. This data also supplements the hypothesis that the magnetic field 
strength used in this project has negligible or no effect on the skin structure and permeability. 
 
Figure 6-3. Representative FT-IR spectra of porcine epidermis in absence of magnetic field (A), 
presence of magnetic field (B) and after exposure to magnetic field for 80 h (C). 
 
6.4.3. Magnetokinesis of drug  
Magnetokinesis is a phenomenon of forced propagation of drug molecules under the 
applied magnetic field. Magnetokinesis of molecules and particles under a gradient magnetic 
field has been reported in the past by several research groups (166, 167). There are at least two 
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potential mechanisms that can contribute to magnetokinesis in the present experimental set up; 
magnetorepulsion and magnetohydrokinesis. Magnetorepulsion could be described as driving of 
the drug molecules (due to the repulsive force experienced by the induced diamagnet) in the 
presence of external magnetic field. Magnetohydrokinesis mediated drug transport is due to the 
movement of water across the membrane under the influence of an external magnetic field. 
These mechanisms are comparable to electrorepulsion and electroosmosis in the case of 
iontophoretic transdermal drug delivery. To reassess if magnetokinesis is one of the mechanisms 
leading to transdermal drug permeation enhancement, permeability studies were also carried out 
across the dialysis membrane with a cut-off size of 1000 Da. A nonbiological barrier like dialysis 
membrane was chosen to eliminate any effect of magnetic field on the barrier. Interestingly, 
application of magnetic field (300 mT) enhanced the permeation flux of LH across the dialysis 
membrane also by ~ 4-fold over passive permeation (passive: 10.79±2.26 µg/cm2/h vs. magnet: 
38.98±6.21 µg/cm2/h). These results suggest that magnetokinesis is one of the predominant 
mechanisms responsible for drug permeation enhancement at these applied magnetic field 
strengths. However, these experiments did not differentiate the relative contribution due to 
magnetorepulsion and magnetohydrokinesis. 
Magnetohydrokinesis across the epidermis under the influence of the applied magnetic field was 
investigated by studying the transport of tritiated water across the epidermis. There was a 
significant difference between the water transport flux across the epidermal membrane in the 
absence (32.63±5.25 nl/cm2/h) and presence (57.21±8.63 nl/cm2/h) of magnetic field (300 mT) 
indicating that hydrokinesis could be one of the factors contributing significantly to the overall 
drug transport due to magnetokinesis.  
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Enhanced transport of water would result in proportionately enhanced transport of dissolved 
substances as well. Therefore to add supportive evidence to the magnetohydrokinesis 
phenomenon, transport of 14C-mannitol across the epidermis was investigated. The application of 
magnetic field (300 mT) resulted in ~2.7-fold enhancement (5.18±1.88 ng/cm2/h) in the transport 
flux of mannitol as compared to passive diffusion (1.89±0.49 ng/cm2/h). The contribution of 
magnetohydrokinesis to the drug transport across biological membranes may become more 
apparent when higher magnetic field strengths are applied and may become remarkably 
significant when a more concentrated drug solution is placed in the donor chamber. 
6.4.4. Effect of magnetic field on octanol-water and SC-aqueous vehicle partitioning of 
drug 
One of the predominant factors known to determine the permeation of drugs across the 
skin is the partition coefficient. Generally, chemical permeation enhancers improve the drug 
permeation by increasing the partitioning of drug into the skin lipids. Sun et al. have shown that 
induction of magnetic field enhanced the extraction of acetone due to the increase in partition 
coefficient (168). In the present work, the effect of exposure to magnetic field on the partition 
coefficient of drug between octanol and water phases was investigated. The partition coefficient 
of LH in the absence of magnetic field was 13.80±4.79 and in the presence of magnetic field 
(300 mT) was found to be 28.94±2.11. In the present set up for determination of partition 
coefficient, the aqueous phase was exposed to the magnetic field and the gradient exists along 
the aqueous→organic phase direction. It is likely that the drug molecules are driven to the 
interface along the field gradient which in turn modulates the thermodynamic equilibrium in a 
way that favors more partitioning of drug into the octanol phase. The other potential reason for 
enhanced octanol partitioning of the drug could be due to the changes in the solvent properties 
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due to exposure to the magnetic field. The SC-aqueous vehicle partition coefficient of LH was 
also found to increase to 0.125±0.02 in presence of magnetic field compared to 0.037±0.012 in 
absence of magnetic field.  
6.4.5. Magnetophoresis of lidocaine base 
LB has a better skin permeation property than its salt (LH) as it is relatively more 
lipophilic than LH (log P of LB is 2.02 vs. 1.15 for LH under the present experimental 
conditions). Even in case of LB, an increasing trend in the enhancement factor was observed 
with increasing magnetic field strengths (Table 6-1) (EF= 0.009S+1). However, in general, at any 
given magnetic field strength, the enhancement factor was higher in case of LH than LB.  This 
appears to be just because the passive permeation flux of LB was ~3-fold higher than that of LH 
(Table 6-1).  
Similar to LH, even in the case of LB, there was no enhancement in permeation flux across the 
porcine epidermis pretreated by exposure to the magnetic field (Table 6-2). When permeation 
studies of LB were performed across the dialysis membrane, an enhancement of ~3-fold was 
observed in the presence of magnetic field (300mT) (passive: 4.95±1.99 µg/cm2/h vs. magnet: 
14.47±3.06 µg/cm2/h).  
The octanol-water partition coefficient of LB was 103.61±4.06 and it was increased to 
128.55±3.91 in presence of magnetic field (300 mT). The SC-aqueous vehicle partition 
coefficient of LB in the presence of the magnetic field (0.171±0.03) was increased when 
compared to that in the absence of magnetic field (0.092±0.01). As compared to the ~110% 
increase in the partition coefficient of LH, the increase in the case of LB was significantly less 
(~24%). Comparable to this, the increase in partition coefficient between SC-vehicle was 
enhanced by ~237% in the case of LH as compared to ~85% in case of LB. This is likely due to 
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the greater inherent ability of LB to partition into octanol or SC lipids as compared to LH. From 
all the above studies it is again evident that the predominant mechanism of drug permeation 
enhancement is likely to be magnetokinesis. Additionally, the enhanced drug partitioning into the 
lipid domain of the stratum corneum could be one of the potential mechanisms contributing, 
which is more apparent in the case of the hydrophilic molecule than the lipophilic molecule.  
6.4.6. Magnetophoretic transdermal patch system        
One of the major tasks that need to be addressed when any physical permeation 
enhancement technique is developed is its applicability in vivo. Techniques such as sonophoresis 
and electroporation have been developed as device based techniques for short duration treatment 
or pretreatment. The drug is delivered during the treatment or post treatment from a formulation. 
Approaches such as iontophoresis and microneedles could be conveniently incorporated into a 
transdermal patch system for prolonged drug delivery (169, 170). Magnetophoresis is a 
phenomenon which occurs only in presence of the magnetic field or it is rather an induced effect. 
Therefore it is more appropriate to incorporate this mechanism in the transdermal patch system 
intended for prolonged application. As a continuation of the transdermal magnetophoresis 
project, a simple transdermal patch system incorporated with magnetic field as the backing layer 
was designed for in vivo drug delivery applications. A patch system with better aesthetic 
appearance and workability could be made by improving the proposed system. LH and LB gels 
were prepared using HPMC (4% w/v) for use as a drug reservoir in the patch system. The 
backing membrane consists of a sequence of magnets arranged in parallel. The control patch was 
developed by using similar nonmagnetic metal pieces in the backing layer. The design of patch 
system is shown in Figure 6-4. 
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Figure 6-4. Photographs of magnetophoretic patch system used for in vivo studies. In Figure a, 
the magnetic backing could be clearly seen as it is not filled with the gel. In Figure b, the gel is 
filled in the cavity ‘B’ (1.5 cm length, 1 cm width and 0.1 cm thickness) above the magnets. ‘A’ 
is the adhesive membrane to secure the patch onto the skin. 
 
6.4.7. Transdermal drug delivery in vivo in rats 
In vivo studies were carried out in rats whereas porcine epidermis was used for all the in 
vitro studies. Though in vitro and in vivo data cannot be correlated due to the use of different 
skin models, the in vivo data with rat model would supplement the findings from in vitro studies 
and thus demonstrate the workability of the technique. Cutaneous microdialysis was employed as 
a tool to investigate the time course of drug concentration in the skin. The in vivo microdialysis 
probe recovery was found to 28.3±5.2 and 12.9±3.8% for LH and LB respectively. The patch 
systems were applied on the abdomen region of rats. The time course of drug in the skin 
extracellular fluid upon application of control and magnetophoretic transdermal patch systems is 
shown in Figure 6-5 and 6-6 for LH and LB respectively. 
 
a b 
A 
B 
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Figure 6-5. Time course of LH in the skin extracellular fluid following application of passive 
transdermal patch (■) and magnetophoretic transdermal patch (●) in rats. 
 
The area under the curve (AUC0-6h) which represents the dermal bioavailability and the 
maximum concentration (Cmax) for both the salt and base forms of drug are given in Table 6-3. 
LB being more lipophilic tends to permeate in higher amounts into the skin compared to LH. 
Moreover, the use of ethanol for incorporating the lipophilic LB in the aqueous gel systems 
might have also lead to enhanced passive drug permeation. The AUC0-6h was ~2-3-fold higher in 
case of magnetophoretic patch system as compared to nonmagnetic control patch system (Table 
6-3). 
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Figure 6-6. Time course of LB in the skin extracellular fluid following application of passive 
transdermal patch (■) and magnetophoretic transdermal patch (●) in rats. 
 
 
Table 6-3. AUC0-6h and Cmax of LH and LB in the skin extracellular fluid following transdermal 
application of passive and magnetophoretic patch systems in vivo  in rats. 
 
Parameter 
LH LB 
Passive 
patch 
Magnetophoretic 
patch 
Passive 
patch 
Magnetophoretic  
Patch 
AUC0-6h 
(µg.h/ml) 10.57 ± 2.05 23.02 ± 2.96 25.21 ± 4.05 53.96 ± 2.63 
Cmax (µg/ml) 2.03 ± 0.26 4.56 ± 0.16 4.87 ± 0.48 10.39 ± 0.72 
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6.5. CONCLUSIONS 
Transdermal magnetophoresis is a phenomenon of the application of magnetic field to 
enhance the drug delivery across the skin. This study demonstrates that the magnetic field could 
be utilized to enhance the drug delivery across the skin. The magnetic field is believed to be a 
relatively safer technique for use on skin as it was found to have no effect on the skin structure at 
the field strengths utilized in this project. The in vivo studies demonstrated the feasibility of 
developing a magnetophoretic transdermal patch system. The magnetophoretic patch systems 
deliver drugs at a higher rate than the nonmagnetophoretic patch systems.  
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CHAPTER-7 
MAGNETOPHORESIS IN COMBINATION WITH CHEMICAL ENHANCERS FOR 
TRANSDERMAL DRUG DELIVERY 
 
7.1. ABSTRACT 
  The objective of the present project was to investigate the effect of combination of 
magnetophoresis, a novel physical permeation enhancement technique and chemical permeation 
enhancers on the transdermal delivery of drugs. The in vitro drug permeation studies were 
carried out across freshly excised abdominal skin of Sprague-Dawley rats using transdermal 
patch systems (magnetophoretic and non-magnetophoretic) of lidocaine hydrochloride. 
Lidocaine hydrochloride gel prepared using HPMC was spread over the magnets as a thin layer. 
To investigate the effect of chemical permeation enhancers, menthol, DMSO, SLS and urea (5% 
w/v) were incorporated in the gels prior to loading on the patch system. The amount of drug 
permeated across the skin was estimated by withdrawing samples from receiver compartment at 
different time points. The permeation flux of lidocaine from magnetophoretic patch was about 3-
fold higher (3.07±0.6 µg/cm2/h) than that of the control (non magnetic patch) (0.94±0.3 
µg/cm2/h). Incorporation of chemical permeation enhancers in the gel enhanced the 
magnetophoretic permeation flux by ~5-7-fold. The enhancement factor due to combination of 
chemical permeation enhancer and magnetic field was found to be additive of the individual 
effects. From the mechanistic studies, magnetic systems were found to enhance the drug 
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permeation via follicular pathway whereas the chemical enhancers increase the permeability of 
bulk of the epidermis.  
Keywords: Transdermal patch system, Follicular pathway, Chemical permeation enhancers, 
Magnetophoresis. 
7.2. OBJECTIVES AND SIGNIFICANCE 
The objectives of the study are: 
I. To investigate the effect of chemical permeation enhancers on the magnetophoretically 
mediated transdermal drug delivery. 
II. To investigate the potential mechanisms contributing to the drug delivery enhancement 
across skin, when chemical enhancers and magnetophoresis are used in combination. 
Various chemical enhancers and physical permeation enhancement techniques have been 
investigated for overcoming the stratum corneum barrier and enhancing the transdermal delivery 
of drugs (171-173). In general, physical permeation enhancement techniques are more efficient 
than chemical enhancers. Several research groups have studied the effect of combination of 
chemical enhancers and physical permeation enhancement techniques like iontophoresis, 
electroporation and ultrasound to assess the plausibility of deriving synergistic benefits. Use of a 
combination of enhancers is reported to mutually enhance the efficacy and also increase the 
safety of enhancers. Oh et al. have reported that the transdermal transport of zidovudine was 
enhanced synergistically when iontophoresis was used in combination with chemical enhancers 
like propylene glycol and oleic acid (174). Ganga et al. showed that the combination of azone 
and iontophoresis enhanced transdermal permeation of metoprolol synergistically (175). 
Combination of ultrasound and sodium lauryl sulfate was reported to result in synergistic 
enhancement in permeation of mannitol by Mitragotri et al. (176). Magnetophoresis is a 
92 
 
phenomenon of enhancing drug permeation across the biological barriers by application of 
magnetic field. Previous work by Murthy et al. has shown that magnetophoresis leads to 
enhanced transdermal drug delivery in in vitro and in vivo studies (177). The predominant 
mechanism for drug permeation enhancement was found to be magnetokinesis and enhanced 
partitioning of drug into stratum corneum. In this study, the experimental data regarding 
permeation enhancement of lidocaine hydrochloride using chemical enhancers and magnetic 
field will be provided first followed by mechanistic studies (157, 178). 
7.3. MATERIALS AND METHODS 
7.3.1. Materials 
Lidocaine Hydrochloride (LH) was obtained from Spectrum Chemicals (New Brunswick, 
NJ), Estradiol, Ferric pyrophosphate, Menthol, Dimethyl sulfoxide (DMSO) and Sodium lauryl 
sulfate (SLS) were purchased from Sigma-Aldrich Inc (St. Louis, MO). PBS 10x liquid 
concentrate and Urea were procured from EMD Chemicals Inc (Cincinnati, OH) and all other 
chemicals and reagents were obtained from Fischer Scientific (Fairway, NJ). Neodymium 
magnets were purchased from K&J Magnetics Inc (Jamison, PA). 
7.3.2. Drug transport from transdermal patch systems  
The in vitro transport of lidocaine hydrochloride from transdermal patch systems across 
the freshly excised rat abdominal skin was studied using vertical Franz diffusion cells 
(diffusional area of 0.64 cm2 and receiver compartment volume of 5 ml). The barrier integrity of 
rat skin was confirmed by measuring the electrical resistance according to previously published 
methods and pieces of skin which had a resistance greater than 20 kΩ.cm2 were only used for the 
drug permeation studies  
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The design of transdermal patch system was similar to that described in section 6.3.12 and 
Figure 6-4. Lidocaine hydrochloride (2% w/w) containing gel was prepared in HPMC base (4% 
w/v) using deionized water and was spread over the magnets as a thin layer, which acts as drug 
reservoir. DMSO, urea and SLS were incorporated in the gels prepared in deionized water 
whereas menthol was incorporated in gel prepared in hydroalcoholic solution (water:alcohol, 
70:30). The receiver compartment of diffusion cell was filled with PBS and drug permeation 
studies were carried out by placing gel filled transdermal patches over the skin with samples 
withdrawn at regular intervals of time over a period of 8 h. 
7.3.3. Drug permeation studies across sandwich epidermis model 
The mechanistic studies were carried out across the sandwich epidermis model prepared 
from porcine epidermis. Sandwich epidermis model includes a layer of stratum corneum sample 
placed over porcine epidermis. Stratum corneum samples are prepared from porcine epidermis 
floated overnight on a aqueous solution containing 0.0001% w/v of trypsin and 0.5% w/v sodium 
bicarbonate at 37 ○C according to method followed by Essa et al. and El Maghraby et al. (157, 
178). 
Passive and iontophoretic delivery of lidocaine hydrochloride, estradiol, and ferric 
pyrophosphate were carried across sandwich epidermis and single layer epidermis and the steady 
state flux was calculated. In case of lidocaine hydrochloride transport studies, the receiver 
compartment of diffusion cell was filled with 5 ml of PBS, pH 7.4 and donor compartment was 
filled with 0.5 ml of lidocaine hydrochloride (10 mg/ml) in PBS, pH 7.4. In case of estradiol 
transport studies, the receiver compartment was filled with 5 ml of PBS, pH 7.4 containing 10% 
HPßCD and the donor compartment was filled with 0.5 ml of estradiol (0.25 mg/ml) in PBS, pH 
7.4 containing 40% alcohol. In case of ferric pyrophosphate transport studies, the receiver 
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compartment was filled with 5 ml of PBS, pH 5 and the donor compartment was filled with 0.5 
ml of ferric pyrophosphate (50 mg/ml) in PBS, pH 5. Anodal iontophoresis was carried out for 
lidocaine hydrochloride and estradiol, whereas cathodal iontophoresis was used for ferric 
pyrophosphate. In all the cases, 0.3 mA/cm2 of electric current was applied using an Iomed 
Phoresor.   
7.3.4. Analytical method 
The amount of lidocaine hydrochloride, estradiol were analyzed by high performance 
liquid chromatography and ferric pyrophosphate was analyzed by UV spectrophotometer. The 
HPLC system (Waters, MA) consisted of a chromatographic pump (Waters 1525), autosampler 
(Waters 717 plus) and an UV absorbance detector (Waters 2487). Symmetry® C18 column (4.6 x 
150 mm) was used for analysis of lidocaine hydrochloride and the mobile phase consisted of a 
mixture (14/86 v/v) of acetonitrile and potassium dihydrogen phosphate 0.05 M (pH adjusted to 
4.0) with a flow rate of 1.3 ml/min at 216 nm (158). Phenomenox® Luna C18 column (4.6 x 150 
mm) was used for analysis of estradiol and the mobile phase consisted of mixture of acetonitrile 
and 0.1% ortho-phosphoric acid (6:4) with a flow rate of 1 ml/min at 212 nm (179). Ferric 
pyrophosphate samples were analyzed at 510 nm using UV spectrophotometer after the addition 
of Ferrover® reagent (180). 
7.3.5. Statistical analysis 
Statistical analysis was carried out using GraphPad InStat 3 software. Unpaired t-test was 
performed and P<0.05 was considered as the level of significance. All the data are represented as 
average of 3-5 trials with standard deviation. 
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7.4. RESULTS AND DISCUSSION 
7.4.1. Development of transdermal patch system incorporated with chemical enhancer and 
magnetic backing  
The magnetophoretic patch system consists of magnets arranged in parallel on the 
adhesive backing membrane. A row of magnetic blocks were used instead of a single magnet 
mainly to impart flexibility to the patch system. Magnets in the backing membrane were replaced 
with nonmagnetic pieces in case of non-magnetophoretic patches. The patches containing 
nonmagnetic backing were used to study the effect of chemical permeation enhancers on the 
delivery of drug from the patch system. The drug along with chemical enhancers incorporated in 
the gel was filled into the cavity of adhesive backing membrane. About 200 mg of gel was 
loaded onto the patch system which contained lidocaine hydrochloride equivalent to 2 mg. 
Different chemical enhancers were incorporated into the gel to enhance the drug permeation 
across the skin. DMSO is known to be an effective permeation enhancer for both hydrophilic and 
lipophilic drugs. On application to skin, DMSO is known to denature the proteins and change the 
confirmation of intercellular keratin from α helical to ß sheet and also interacts with the 
intercellular lipid regions of the stratum corneum (181-183). Terpenes have been reported to be 
safe and effective permeation enhancers for both hydrophilic and lipophilic drugs (184). Menthol 
has been studied as permeation enhancer for hydrophilic drugs like 5-fluorouracil and 
propranolol hydrochloride (185, 186). The main reason for enhancement of permeation of 
hydrophilic drugs by menthol is due to the disruption of the stratum corneum lipids by breakage 
of hydrogen bonds between the ceramide groups (187). Urea has been known to act as a skin 
permeation enhancer by increasing the stratum corneum water content and thus leading to 
opening of hydrophilic diffusion channels within the stratum corneum. SLS is known to 
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solubilize the stratum corneum lipids and also interact with keratin to enhance the overall skin 
permeability (39, 149). 
7.4.2. Magnetophoresis mediated drug delivery enhancement 
The passive permeation flux of lidocaine hydrochloride across rat skin was found to be 
0.94±0.13 µg/cm2/h. The permeation flux of lidocaine hydrochloride was enhanced by ~3-fold 
(3.07±0.43 µg/cm2/h) in case of magnetophoretic patch system compared to that of passive.  
7.4.3. Effect of chemical enhancers on the drug delivery from transdermal patch systems 
Incorporation of chemical enhancers has resulted in an increase in the permeation flux of 
lidocaine hydrochloride compared to control (gel without any chemical enhancer). The 
concentration of all the four enhancers used in the present study was at 5% w/v. The drug 
permeation enhancement factor of different enhancers could be represented in the following 
decreasing rank order: menthol > SLS > urea > DMSO. Incorporation of menthol in the gel 
formulation resulted in ~3.7-fold enhancement (3.50±0.69 µg/cm2/h) in the flux of lidocaine 
hydrochloride. Due to limited solubility of menthol in the aqueous vehicle, 30% v/v of alcohol 
was used in the gel formulation to incorporate menthol (the flux enhancement by 30% v/v 
alcohol alone in absence of menthol was found to be ~1.4-fold over control). SLS resulted in 
~2.6-fold enhancement (2.44±0.39 µg/cm2/h) in the permeation flux over the control patch. On 
the other hand, urea and DMSO lead to ~1.7-fold (1.62±0.27 µg/cm2/h) and ~1.1-fold (1.07±0.24 
µg/cm2/h) enhancement in the flux over the control patch. Among the enhancers, menthol and 
SLS resulted in greater enhancement compared to urea and DMSO. Except DMSO, all the other 
chemical enhancers showed a significant enhancement in the flux of lidocaine hydrochloride 
(Figure 7-1).  
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Figure 7-1. Transdermal permeation flux of lidocaine hydrochloride from non-magnetophoretic 
patch systems. ‘Control’ indicates patch system without any chemical enhancer. ** indicates 
statistically insignificant and * indicates statistically significant compared to control. 
 
The effect of pretreatment was not considered because the effective pretreatment varies with 
each chemical enhancer and would not clearly reflect the relative efficiency. Moreover, in real 
life situation, the patch containing combination of chemical enhancers and magnetophoresis will 
be applied by the patients. Therefore, the studies included simultaneous application of both the 
enhancers (chemical enhancers and magnetophoresis) in the patch system to simulate the in vivo 
practice.  
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7.4.4. Effect of combination of chemical enhancers and magnetophoresis on the drug 
delivery  
Combination of chemical enhancers and magnetophoresis resulted in enhanced 
permeation flux compared to both individual chemical enhancer effect and magnetophoretic 
effect and was additive in most of the cases (Table 7-1). Definitely, there was a significant 
increase in the enhancement efficiency with this combination approach. Moreover, the results 
clearly demonstrated the feasibility of incorporating chemical permeation enhancers and 
magnetophoresis technique in a simple transdermal patch system, which could be of potential 
benefit in enhancing the transdermal delivery of poorly permeable drugs. The plausible reason 
for an additive effect is likely due to the difference in the predominant mechanism of drug 
delivery enhancement between the chemical enhancers and magnetophoresis. Among the 
enhancers used, menthol and SLS are known to act predominantly on the lipoidal regions 
whereas DMSO and urea act on the keratinocytes. Our earlier studies have shown that the 
magnetically mediated transdermal drug delivery is more likely due to interaction of the 
magnetic field with the drug molecule than with the stratum corneum barrier. In the mechanistic 
studies sandwich epidermis model was used to elucidate the predominant mechanism of 
enhancement of drug delivery by the application of magnetic field.  
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Table 7-1. Transdermal permeation flux of lidocaine hydrochloride from non-magnetophoretic 
and magnetophoretic patch system. ‘Control’ in the table indicates patch system without any 
chemical enhancer. Enhancement factor is the ratio of permeation flux obtained with respect to 
flux from control (non-magnetophoretic patch system). 
 
Enhancer 
Non-magnetophoretic patch Magnetophoretic patch 
Permeation flux 
(µg/cm2/h) 
Enhancement 
Factor 
Permeation flux 
(µg/cm2/h) 
Enhancement 
Factor 
Control 0.94 ± 0.13 1.00 3.07 ± 0.43 3.26 
DMSO 1.07 ± 0.24 1.13 3.82 ± 0.48 4.06 
Urea 1.62 ± 0.27 1.72 4.85 ± 0.24 5.15 
SLS 2.44 ± 0.39 2.59 4.93 ± 0.37 5.24 
Menthol 3.50 ± 0.69 3.72 6.06 ± 0.43 6.44 
 
 
7.4.5. Mechanistic studies 
In a recent report, the results of the mechanistic studies clearly demonstrated that 
magnetokinesis was the predominant mechanism responsible for enhanced transdermal 
permeation (177). However, the relative contribution of appendageal pathway in magnetokinesis 
has not been investigated. Mechanistic studies were carried out using sandwich epidermis model 
developed by El Maghraby et al. to elucidate the role of appendageal pathway in drug 
permeation across the skin (178). In the sandwich epidermis model, the stratum corneum layer 
overlaid on the epidermal membrane forms the top layer and blocks most of the appendageal 
pathways present in underlying epidermal membrane (Figure 7-2). 
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Figure 7-2. Sandwich epidermis model. 2a represents single layer epidermis with unblocked 
appendageal pathway and 2b represents sandwich epidermis with a stratum corneum layer 
overlaid on the epidermal membrane. Appendageal pathway of underlying epidermal membrane 
is blocked by the overlaid stratum corneum layer and appendageal pathway of the overlaid 
stratum corneum layer is blocked by the underlying epidermal membrane. In case of sandwich 
epidermis, the permeation flux of hydrophilic drugs which permeate mostly through appendageal 
pathway would be reduced by less than half and be close to zero due to blockage of appendageal 
pathway. However, the permeation flux of lipophilic drugs which permeate mostly through the 
bulk of epidermis (non-appendageal pathway) would be reduced by half due to increase in 
thickness of the barrier, in the case of sandwich epidermis. 
 
In this study porcine epidermis was used to carry out mechanistic studies using sandwich model 
due to ease of separation of epidermis when compared to rat skin. El Maghraby et al. have 
carried out permeation studies across the sandwich epidermis and compared it with that across 
the epidermis alone (178). The authors reported that the permeation through sandwich epidermis 
model would be much reduced in comparison to epidermis if appendageal pathway played an 
active role in the permeation of drug. It was reported that appendageal pathway played only a 
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minor role in the penetration of liposomal formulations containing estradiol. Essa et al. used the 
same model to examine the role of skin appendages in the passive, iontophoresis and liposomal 
penetration of drugs and reported that the appendageal pathway played a major role in the 
passive permeation of hydrophilic mannitol, where as it was negligible in case of lipophilic 
estradiol (157). The authors also reported that the appendageal pathway had a significant role in 
the flux enhancement by iontophoresis (157, 178). 
Initially, a few set of experiments were dedicated to validate the sandwich epidermis model 
reported by El Maghraby et al. Permeation studies were carried out using lidocaine 
hydrochloride, estradiol and ferric pyrophosphate. Lidocaine hydrochloride is a cationic 
hydrophilic drug and estradiol is lipophilic in nature. Ferric pyrophosphate represents a high 
molecular weight anionic hydrophilic compound. Therefore, the three marker drugs differ in 
their extent and pathways of transdermal permeation.  
7.4.5.1. Passive permeation studies across sandwich epidermis and single layer epidermis 
 The passive permeation flux ratio of sandwich model to single layer epidermis (FSW/SL) 
would be close to 0.5, if appendageal pathway had no role in drug permeation and the FSW/SL 
would be <0.5 and close to zero if the drug permeation was via appendageal pathway. In general, 
highly hydrophilic drugs permeate through skin mainly via appendageal pathway whereas 
lipophilic drugs permeate mainly through the bulk of the skin (188, 189). Based on this one 
would expect FSW/SL would be <0.5 for lidocaine hydrochloride and ferric pyrophosphate which 
are hydrophilic and 0.5 for estradiol which is lipophilic in nature.   
The steady state flux of lidocaine hydrochloride was found to be 1.45±0.02 µg/cm2/h across the 
single layer porcine epidermis. The flux decreased significantly to 0.24±0.01 µg/cm2/h across the 
sandwich epidermis (Figure 7-3). The FSW/SL was ~0.16 indicating that the appendageal pathway 
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had a significant role in the passive permeation of lidocaine hydrochloride (Table 7-2). However, 
the diffusion across the bulk of the epidermis is not completely negligible in this case. This is 
likely because of the presence of unionized fraction of the drug, which tends to selectively 
diffuse via bulk of the epidermis pathway.   
 
Figure 7-3. Passive permeation of lidocaine hydrochloride across single layer (●) and sandwich 
epidermis (■). 
 
The passive permeation flux of estradiol was found to be 0.042±0.004 µg/cm2/h and 0.023±0.003 
µg/cm2/h across single layer epidermis and sandwich epidermis respectively with FSW/SL of 0.54 
(Figure 7-4, Table 7-2). The results indicate that the appendageal pathway did not play a 
significant role in the permeation of lipophilic estradiol and hence the flux was reduced by 
almost half across the sandwich epidermis. This was in agreement with the results reported by 
Essa et al. for estradiol permeation across the human epidermis (157). 
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Ferric pyrophosphate did not result in any passive permeation across the porcine epidermis 
which could be due its high molecular size and extremely hydrophilic nature.  
 
Figure 7-4. Passive permeation of estradiol across single layer (●) and sandwich epidermis (■). 
7.4.5.2. Iontophoretic drug delivery across sandwich and single layer epidermis 
 Anodal iontophoresis would favor the transdermal delivery of lidocaine hydrochloride 
and at pH over 5, both electroosmosis and electrophoresis contribute to the enhanced transport of 
drug. In case of estradiol, permeation could be enhanced only by electroosmosis mechanism due 
to lack of any charge on the molecule (157). Ferric pyrophosphate was found to be poorly 
permeable across the skin by passive diffusion and the permeation could be enhanced 
significantly by cathodal iontophoresis at pH over 5. In case of ferric pyrophosphate, recent 
studies by Murthy and Vaka have shown that electroosmosis does not play any role in the 
enhanced permeation and the main pathway for enhanced permeation by iontophoresis is through 
appendageal pathway (180). So, in the present study, anodal iontophoresis was carried out for 
lidocaine hydrochloride and estradiol whereas cathodal iontophoresis was carried out for ferric 
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pyrophosphate. The flux of lidocaine hydrochloride across sandwich epidermis decreased to 
2.86±0.63 µg/cm2/h in comparison to 12.54±1.98 µg/cm2/h across single layer epidermis and 
IFSW/SL (ratio of iontophoretic flux across sandwich model to single layer epidermis) was found 
to be 0.22 (Figure 7-5, Table 7-2). In case of estradiol IFSW/SL was found to be 0.19 with a flux of 
0.022±0.002 µg/cm2/h across the sandwich epidermis model and 0.111±0.007 µg/cm2/h in case 
of single layer epidermis (Figure 7-6, Table 7-2). Assuming complete blockade of appendageal 
pathway, IFSW/SL should be close to zero. But permeation of both lidocaine and estradiol was 
observed which might be due to the electroosmosis mediated transport of drug through the 
additional pores created in the bulk of the skin by application of iontophoresis. These results are 
in agreement with that reported by others (157, 178). Murthy and Vaka demonstrated that the 
iontophoretic delivery of ferric pyrophosphate occurs only through appendageal pathway across 
the rat skin (180). In this study using porcine epidermis, IFSW/SL of ferric pyrophosphate was only 
0.04, with flux of 1.58±0.10 µg/cm2/h and 37.69±4.68 µg/cm2/h across sandwich and single layer 
epidermis respectively (Figure 7-7, Table 7-2). These results of the validation studies confirm 
that the appendageal pathway is almost completely blocked in the sandwich epidermis model and 
it could serve as an excellent model to investigate the contribution of appendageal pathway in the 
drug transport. Barry has also proposed that sandwich epidermis model can be applied 
effectively to analyze appendageal pathway in case of ultrasound and magnetophoresis studies in 
addition to passive diffusion and electrical methods (190). Therefore, the sandwich epidermis 
model was used in case of magnetophoresis mediated studies to elucidate the mechanism of 
appendageal pathway. 
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Figure 7-5. Iontophoretic delivery of lidocaine hydrochloride across single layer (●) and 
sandwich epidermis (■). 
 
Figure 7-6. Iontophoretic delivery of estradiol across single layer (●) and sandwich epidermis 
(■). 
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Figure 7-7. Iontophoretic delivery of ferric pyrophosphate across single layer (●) and sandwich 
epidermis (■). 
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Table 7-2. Steady state flux of lidocaine hydrochloride, estradiol, and ferric pyrophosphate 
following passive permeation and iontophoretic delivery across sandwich and single layer 
epidermis with corresponding flux ratios. 
 
Drug 
Flux (µg/cm2/h) Flux ratio (sandwich
/single 
layer) 
Role of 
appendageal 
pathway 
Sandwich 
epidermis 
Single layer 
epidermis 
Passive permeation 
Lidocaine 
Hydrochloride 0.24 ± 0.01 1.45 ± 0.02 0.16 Significant  
Estradiol  0.023 ± 0.003 0.042 ± 0.004 0.54 Insignificant  
Ferric 
pyrophosphate - - - - 
Iontophoretic delivery 
Lidocaine 
Hydrochloride a 2.86 ± 0.63 12.54 ± 1.98 0.22 Significant 
Estradiol b  0.022 ± 0.002 0.111 ± 0.007 0.19 Significant 
Ferric 
pyrophosphate c 1.58 ± 0.10 37.69 ± 4.68 0.04 Significant 
aAnodal iontophoresis       bAnodal iontophoresis     cCathodal iontophoresis  
The potential mechanisms are electroosmosis and electrorepulsion in case of b and c 
respectively. In case of a both electrorepulsion and electroosmosis contribute together.  
 
7.4.5.3. Magnetophoretic delivery of lidocaine hydrochloride across sandwich and single 
layer epidermis 
 These studies were carried out to determine the extent of contribution of appendageal 
pathway in magnetically enhanced drug permeation. Drug permeation studies were carried out 
across porcine epidermis using transdermal patch system. The flux of lidocaine hydrochloride 
from magnetophoretic patch system across single layer epidermis and sandwich epidermis was 
found to be 3.87±0.30 µg/cm2/h and 0.99±0.26 µg/cm2/h respectively. The MFSW/SL (ratio of 
magnetophoresis flux across the sandwich model to single layer epidermis) would have been 
close to 0.5 if appendageal pathway had no significant role in the drug permeation by 
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magnetophoresis. But, MFSW/SL was found to be 0.25 indicating that appendageal pathway played 
a significant role in the magnetophoretic delivery of lidocaine hydrochloride.  
From the mechanistic studies reported earlier and in the present paper, it is more evident that the 
magnetic field enhances the drug delivery across the skin predominantly by magnetokinesis 
across the appendageal pathway without significantly affecting the stratum corneum barrier. In 
addition, the present study indicates that the use of chemical permeation enhancers which 
interact with the bulk of the epidermis (non appendageal region) would improve the overall drug 
delivery efficiency. 
7.5. CONCLUSIONS  
  The results indicate that the magnetically mediated drug permeation enhancement could 
be further enhanced by incorporation of suitable chemical permeation enhancers. The magnetic 
systems were found to enhance the drug permeation via appendageal pathway.  
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